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ABSTRACT 
Pregnenolone (PREG), the precursor of all neurosteroids, is synthesized in the 
nervous system from cholesterol and recent clinical studies indicate that reduced 
cognitive symptoms of schizophrenia correlate with elevated serum levels of 
pregnenolone sulfate (PregS), its immediate sulfated metabolite. PregS fulfills most of 
the classical criteria for an endogenous modulator of excitatory synaptic transmission, 
including: presence in nervous tissue at physiologically relevant concentrations, 
potentiation of N-methyl-D-aspartate receptor (NMDAR) mediated synaptic activity, and 
a mechanism for its inactivation. As NMDAR hypoactivity has been implicated in the 
pathophysiology of schizophrenia, defects in neurosteroid metabolism might play a role 
in its associated cognitive dysfunction. 
 PregS improves memory performance in rodents and augments long-term 
potentiation (LTP), an electrophysiological correlate of synaptic plasticity that is 
stabilized by phosphorylation of the cAMP response element binding protein (CREB). 
We have previously demonstrated that PregS at low picomolar (pM) concentrations 
increases intracellular Ca2+ and CREB via synaptic NMDARs. Therefore, we 
hypothesized that low pM concentrations of PregS might potentiate spontaneous 
excitatory postsynaptic currents (sEPSCs) and promote molecular events underlying 
 viii 
synaptic plasticity. Here, using whole-cell patch clamp recordings, we report that PregS 
enhances the frequency of sEPSCs of cultured hippocampal neurons by about 2-fold 
while not altering their amplitude or passive membrane properties. This suggests that 
PregS acts presynaptically by increasing the frequency of neurotransmitter release or 
postsynaptically by activating silent synapses. We then investigated the hypothesis that 
PregS increases α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAR) and NMDAR subtypes at synapses as a molecular switch for this 
enhancement. We measured receptor redistribution and phosphorylation using 
fluorescence imaging and Western blot technology. The results demonstrate that PregS 
(50pM, 10min): (1) Increases AMPAR (GluA1)/PSD95 colocalization (dependent on L-
type voltage-gated Ca+2 channel and synaptic NMDAR activity), and increases 
phosphorylation of GluA1 at serine-831/845; (2) Increases casein kinase 2 (CK2) 
dependent surface NMDAR2A (GluN2A) but not GluN1 or GluN2B; and (3) Increases 
GluN2B serine-1480 phosphorylation. The results show that PregS increases the 
frequency of excitatory synaptic transmission and increases surface/synaptic AMPARs 
and surface GluN2A (but not GluN1 or GluN2B) NMDARs, shifting the molecular 
composition of young glutamatergic synapses toward the adult GluN2A enriched 
synaptic phenotype.  
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Chapter 1 
 
1. Pregnenolone Sulfate  
a. Overview of neurosteroids and neuroactive steroids 
 For more than two decades it has been known that the central nervous system 
(CNS) is a steroidogenic organ that can synthesize steroids (neurosteroids) locally de novo 
from cholesterol derived primarily from circulating lipoproteins, in addition to taking up 
steroids from the peripheral blood (Schumacher and Baulieu, 1999; Baulieu, 1997). 
Neurosteroids have been shown to act on intracellular steroid receptors, whereupon 
binding, the receptor-ligand complex is translocated into the nucleus and augments or 
suppresses transcription (Tata 2002). However, in addition to their genomic actions, 
neurosteroids can induce immediate cellular responses by modulating the function of 
neurotransmitter receptors, leading to their description as “neuroactive steroids”. They 
have been shown to allosterically modulate neurotransmitter receptors such as γ-
aminobutyric acid type A (GABAA), NMDA, kainate, and sigma receptors (Baulieu et al, 
1998, Tsutsui, 2007). Neurosteroids include pregnenolone and dehydroepiandrosterone 
(DHEA), their sulfates PregS and dehydroepiandrosterone sulfate (DHEAS), estradiol, 
progesterone and allopregnanolone. Steroid hormones have been shown to increase 
neuronal survival, induce growth of neurites and formation of synaptic connections during 
the early stages of development and play an important role in synaptic plasticity in the 
adult. In the event of injury or disease, steroid hormones have been reported to be 
neuroprotective by supporting neuroregenerative processes (Schumacher et al., 2000). 
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Steroid synthesis is regulated by the steroidogenic acute regulatory (StAR) protein, which 
controls the transport of cholesterol from the outer mitochondrial membrane to the inner 
mitochondrial membrane. StAR acts on the outer mitochondrial membrane via a multi-
protein complex consisting of the mitochondrial transporter protein (TPSO), voltage-
dependent anion channel (VDAC1), the adenine nucleotide transporter (ANT), the 
diazepam-binding inhibitor (acyl-CoA-binding domain 1, ACBD1), the TSPO-associated 
protein-1 (PRAX-1), and the PKA regulatory subunit RIα-associated protein 7. The 
complex aids StAR in moving cholesterol to the inner mitochondrial membrane and 
inducing steroidogenesis. This is where the cholesterol side-chain cleavage enzyme, 
P450scc converts insoluble cholesterol to soluble pregenenolone – the first and rate-
limiting step in steroidogenesis (Baulieu et al, 1998, Miller, 2007).   
 
b. PregS synthesis and transport 
The neuroactive steroid PregS is synthesized via the sulfation of pregnenolone 
(PREG), catalyzed by sulfotransferases, which transfer a sulfonate group (SO3
-) from 3’-
phosphoadenosine-5’-phosphosulfate to the hydroxyl group of PREG. Steroid sulfatase 
converts PregS to the unconjugated form (Schumacher et al., 2008). More than 40 cytosolic 
sulfotransferase enzymes (SULT) have been identified from which SULT2A1, SULT2B1a 
and SULT2B1b have been shown to be involved in the formation of PregS (Strott, 2002). 
The sulfate moiety renders its hydrophilicity, which makes it difficult for the steroid to 
cross the plasma membrane. Transport across the membrane is facilitated by a number of 
transporter proteins, including the organic solute transporter alpha beta (OSTα-OSTβ), 
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which is present in steroidogenic cells of the hippocampus and has a high affinity for PregS 
and DHEAS (Fang et al., 2010).  
 
 
Fig. 1: Conversion of PREG to PregS by the SULT enzyme (Schumacher et al., 2008) 
 
c. Detection of PregS in the brain 
A great deal of debate in the neurosteroid research community has centered on the 
determination of endogenous levels of neurosteroids in the brain and the use of the 
appropriate detection methodology. PregS and DHEAS were among the first neurosteroids 
to be discovered and considered to be the most abundant in the brain. Early studies showed 
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that PregS levels persisted at significant levels in the rat brain (16 ng/g brain tissue) after 
adrenalectomy and castration, implying that they were produced locally in the brain, 
therefore, classifying it as neurosteroid (Corpechot et al., 1981, 1983). In post-mortem 
human brains, high levels of PregS were measured as well (5-38 ng/g brain tissue; Lanthier 
and Patwardhan, 1986).  However, in all these early studies the levels of PregS were not 
directly measured, instead they used liquid-liquid extraction followed by acid solvolysis 
and measured the levels of PREG via a radioimmunoassay with an antibody against the 
unsulfated steroid. Since then, several studies have used more sensitive and direct detection 
methods, such as gas chromatography- mass spectrometry (GC-MS), to determine the level 
of sulfated derivatives of pregnenolone. PregS was not detected in tissue extracts from 
adult rat brain, however, the detection limit for PregS was 141 pM (Ebner et al., 2006). In 
another study, the level of PregS in postmortem human brain was reported to be 2.8 nM 
and 4.6 nM in the frontal cortex and in the cerebellum, respectively (Liere et al., 2004). A 
recent study using liquid chromatographic-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS) method showed that PregS is present in the rat 
hippocampus at maximum bulk concentrations of 26 nM (Rustichelli et al., 2013). 
Therefore, since the actions of PregS studied in in-vitro and ex-vivo assays discussed in the 
next section occur at micromolar and as low as high nanomolar concentrations of PregS, 
questions arise about the physiological significance of the observed neuromodulatory 
effects of PregS. However, knowing the bulk concentrations of PregS in the tissue does not 
necessarily exclude the possibility that locally active concentrations of PregS, for example, 
at the synapse could be much higher (reviewed by Gibbs et al., 2006; Schumacher et al., 
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2008, Smith et al., 2014). 
d. Preclinical studies of PregS  
1. In-vitro and ex-vivo neuromodulatory effects of PregS  
A. Membrane receptor targets of PregS 
            1. NMDA receptors  
The NMDAR belongs to the glutamate ionotropic receptor family and is a 
heterotetramer complex that consists of two GluN1 subunits and two GluN2 subunits (A, 
B, C, and D). The coagonist glycine binds to the GluN1 and glutamate binds to GluN2. 
The receptor structure is made of three transmembrane domains (M1, M3 and M4) and a 
reentrant loop that faces the cytoplasm (M2). The amino-terminus (N-terminus) is 
extracellular, while the carboxyl-terminus (C-terminus) is located intracellularly 
(Dingledine et al., 1999). PregS is a positive modulator of NMDA receptors with an EC50 
of 33 µM. PREG (which lacks a C3-sulfate group) is inactive at NMDARs (Wu et al., 1991, 
Yaghoubi et al., 1998, Gibbs and Farb, 2000). Studies of recombinant NMDAR chimeras 
expressed in Xenopus laevis oocytes have identified a steroid modulatory domain, possibly 
a PregS binding site, on the GluN2 subunit (Jang et al., 2004). The modulation of NMDAR 
by PregS is dependent on the NMDAR subunits present. GluN2A and GluN2B containing 
NMDARs are positively modulated by PregS, whereas GluN2C and GluN2D containing 
NMDARs are negatively modulated (Malayev et al., 2002). Recently, it has been shown 
that PregS enhances the insertion of NMDARs into plasma membrane via a non-canonical, 
pertussis toxin–sensitive, G protein–coupled, and Ca2+-dependent mechanism that is 
independent of NMDA receptor activation (Kostakis and Smith et al., 2013). Sliwinski et 
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al. (2004) have shown that PregS enhances NMDAR-dependent LTP in Cornu Ammonis 
1 (CA1) pyramidal neurons. PregS at 50 µM also induced LTP in the dentate gyrus via 
phosphorylation of tyrosine residues in GluN2B subunit of NMDARs (Chen et al., 2007). 
A presynaptic action of the neurosteroid was also reported by Mameli et al. (2005), 
observing that PregS modulates presynaptic GluN2D subunit containing NMDARs, 
thereby increasing the amplitude of miniature excitatory postsynaptic currents (mEPSCs) 
mediated by AMPA receptors in rat hippocampal slices from postnatal day 3 to 5. Studies 
by our lab and others have discovered that PregS exerts an NMDAR dependent 
neuromodulatory effect at concentrations within the physiological range. In vivo 
microdialysis demonstrates that 10 pM PregS induces an increase in extracellular dopamine 
in striatum, while in a striatal synaptosome preparation 25 pM PregS enhances dopamine 
release via a NMDAR dependent mechanism (Whittaker et al., 2008; Sadri-Vakili, 2008). 
Analysis of PregS modulation of [3H]ifenprodil binding to neuronal membranes or 
GluN1/GluN2B receptors expressed in CHO cells reveal that PregS at nanomolar 
concentrations enhances ifenprodil binding, suggesting that there is a higher affinity mode 
of interaction between PregS and NMDARs (Johansson et al., 2008). Our laboratory has 
also demonstrated that 100 nM PregS potentiates NMDAR-induced currents in Xenopus 
laevis oocytes expressing GluN1A/GluN2A receptors in a manner consistent with the 
insertion of NMDARs to the plasma membrane (Kostakis and Smith et al., 2013). Our 
recent study showed that 50 pM PregS stimulates intracellular Ca2+ increase and promotes 
CREB phosphorylation in rat cultured cortical cells. The effect of PregS on Ca2+ increase 
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is attenuated by ifenprodil, Ro 25-6981, and D-(-)-2-amino-5-phosphonopentanoic acid 
(D-AP5), suggesting a NMDAR dependent process (Smith et al., 2014). 
2. L-type voltage-gated Ca2+channels 
Voltage-gated Ca2+channels are activated by strong depolarization and are 
characterized by large single channel conductance. Based on their sequences, they fall into 
three main groups: CaV1 (L-type), CaV2 (P-type, N-type, and R-type), and CaV3 (T-type). 
L-type voltage-gated Ca2+ channels (L-type VGCC) have been well characterized due to 
their high sensitivity to dihydropyridine agonists and antagonists. They are critical in 
coupling membrane depolarization to gene expression and induction of synaptic plasticity 
(Lipscombe et al., 2004). When testing the effect of PregS on LTP, Sabeti et al. (2007) 
reported that PregS increases LTP at the CA1 synapse via a sigma receptor and L-type 
VGCC activation dependent mechanism in hippocampal slices. In another study, PregS 
stimulation was shown to elevate activity levels of the transcription factor activator protein-
1 (AP-1) and upregulate basic region leucine zipper transcription factors c-Jun and c-Fos 
in insulinoma cells and pancreatic β-cells in primary culture. Blocking the PregS effect 
with verapamil indicated that activation of L-type VGCCs are required in the observed 
activation of gene transcription (Müller et al., 2011). Chen and Sokabe (2005) showed that 
PregS increased perforant path-granule cell synaptic transmission and decreased paired-
pulse facilitation, which they were able to block using nifedipine, an L-type VGCC 
inhibitor. The same group showed that LTP induction using a low frequency stimulation 
of 20 Hz was dependent on L-type VGCCs (Chen et al., 2010).  
 8 
3. TRPM3 channels 
The transient receptor potential (TRP) channel superfamily, one of the largest 
families of ion channels known, consists of weakly voltage-sensitive and largely non-
selective cation influx channels that exist in many species - from yeast to mammals. 
Interestingly, unlike other cation-selective channels, they are not classified based on their 
selectivity or ligand function but on their primary amino acid sequence. In human, the TRP 
superfamily consists of 28 genes and is divided into six subfamilies: TRPC (classical), 
TRPV (vanilloid), TRPM (melastatin), TRPML (mucolipins), TRPP (polycystin), and 
TRPA /ANKTMI (ankyrin transmembrane protein 1) (Huang et al., 2004; Moran et al., 
2004). TRP channels are related to the voltage- and ligand-gated potassium channel family 
and the highest sequence similarity between them is in the transmembrane domain. 
Therefore, reminiscent of potassium channels, all TRP channels are thought to form 
tetramers (homo or hetero) as functional units; an idea that has been confirmed for several 
TRP channels in biochemical studies. The transmembrane domain of each TRP channel 
subunit contains six roughly membrane-spanning helical segments (S1-S6), which can be 
further divided into two building units: the sensor (formed by S1-S4) and the cation-
permeable pore (formed by S5 and S6). The N-and C-terminal extensions are cytosolic 
(Gaudet, Rachelle, 2007). TRPM channels exhibit highly variable permeability to Ca2+ and 
Mg2+, from Ca2+-impermeable (TRPM4 and 5) to highly Ca2+ and Mg2+ permeable 
(TRPM6 and 7). TRPM2, TRPM3, and TRPM8 show a direct influx of Ca2+ in response 
to stimuli (Harteneck, Christian, 2005).  PregS was shown to acts as a direct ligand to 
activate TRPM3 receptors in primary cultured pancreatic β-cells with an EC50 of 27 µM 
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(Wagner et al., 2008). Wagner’s group observed that PregS was able to elicit calcium 
signals in TRPM3 expressing pancreatic beta cells and enhanced insulin secretion. In 
addition to L-type VGCCs, Mayer et al (2011) reported that the activation of TRPM3 was 
required to induce the signaling cascade by PregS which results in the enhanced expression 
of the zinc finger transcription factor Egr-1 and Egr-1-responsive target genes. The 
molecular cell biology of endocrine pancreatic β-cells is remarkably similar to that of 
neurons, in that both express neuronal genes. Pancreatic β-cells express synapsin I, 
synaptophysin or synaptotagmin, neurotransmitters and neurotransmitter synthesizing 
enzymes. Therefore, considering that TRPM3 is highly expressed in the brain, the question 
arises as to whether the physiological effects of PregS include the activation of TRPM3 in 
the brain.  
4. GABAA receptor  
The major inhibitory neurotransmitter in the mammalian brain is GABA. Three 
types of GABA receptors have been identified: GABAA, GABAB, and GABAC. The 
GABAA and GABAC receptors are members of the ligand-gated chloride ion channel 
family (ionotropic), whereas GABAB receptors fall into the group of G-protein coupled 
receptors (metabotropic). GABAA receptors share most of their protein structure with 
nicotinic acetylcholine, 5-Hydroxytryptamine-3 (5-HT3), and strychnine-sensitive glycine 
receptors. This cysteine loop family is characterized by a pentameric protein subunit 
arrangement around a central chloride ion channel or pore, where each subunit is made up 
of a N-terminal extracellular domain, four transmembrane domains (TM1 to 4), and an 
extracellular cysteine-cysteine loop structure between TM2 and TM3 (Berezhnoy et al, 
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2006). The first evidence of PregS having an effect on GABAA receptors was shown by 
Majewska and Schwartz (1987), who reported that PregS inhibited GABA mediated 36Cl- 
uptake by rat brain synaptosomes (cited in Gibbs et al., 2006). In another study, in GABA-
activated single Cl- channels recorded from membrane patches of primary rat cortical 
neurons, PregS decreased the opening frequency of the channels without affecting channel 
conductance or open time (Mienville and Vicini, 1989). Subsequent studies showed that 
PregS is a negative modulator of GABAA receptors with a half maximal inhibitory 
concentration (IC50) of 7.2 µM measured in spinal cord neurons in primary culture. 
Simultaneous application of sulfated and unsulfated steroids to Xenopus laevis oocytes 
overexpressing GABAA receptors show that steroid positive and negative modulators do 
not share a common binding site and act independently (Park-Chung et al., 1999).  
5. Sigma receptors  
The sigma receptor consists of two subtypes -sigma-1 and sigma-2, which can be 
distinguished based on their different drug selectivity profiles and molecular mass. The 
sigma-1 receptor has binding sites for dextrorotatory isomers of benzomorphans, whereas 
sigma-2 receptor has binding sites for levorotatory isomers. The molecular weight of the 
sigma-1 receptor and sigma-2 rececptor is a 29-kDa and 18-21.5 kDa, respectively 
(Maurice and Su, 2009; Cobos et al., 2008). Since the successful cloning of the sigma-1 
receptor, studies have predominately focused on its physiological function, compared to 
the sigma- 2 receptor. Sigma-1 receptors have one transmembrane domain and an 
endoplasmic reticulum (ER) retention signal. In the CNS, the highest levels of the receptor 
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have been observed in cranial nerves, nuclei of mesencephalon, hypothalamus, and 
Purkinje cells and moderate levels were seen in pyramidal cell layer and the dentate gyrus 
of the hippocampus (Hayashi and Su, 2005). Mtchedlishvili and Kapur (2003) reported that 
PregS reduced the frequency of both action potential-dependent spontaneous inhibitory 
postsynaptic currents (sIPSCs) and independent miniature IPSCs in cultured hippocampal 
pyramidal neurons.  They were able to block the effect of PregS with a sigma-1 receptor 
antagonist BD-1063. In a different study, sigma-1 receptors were also implicated in the 
enhanced presynaptic function elicited by PregS application in rat hippocampal slices 
(Sabeti et al., 2007). More recently, Yang et al. (2011) showed that PregS increased 
presynaptic glutamate release at perforant path-granule cell synapses that was dependent 
on sigma-1 receptors, in addition to NMDA and alpha 7 nicotinic acetylcholine receptors 
(α7nAChR).  
B. Transcription factors 
1. CREB 
Cyclic AMP response element-binding protein (CREB) is a cellular transcription 
factor that has been found to facilitate neuronal differentiation, survival, and synaptic 
plasticity (Anderson, 2007; Collingridge et al., 2010). It binds to the cAMP-response 
element (CRE), a sequence found in the promotor region of many inducible genes resulting 
in coordinated induction of transcription (Impey et al., 2004). The first study to describe 
PregS increasing CREB phosphorylation was by Chen et al. (2007), who demonstrated that 
50 µM PregS induced LTP in the dentate gyrus via phosphorylation of tyrosine residues in 
GluN2B subunit of NMDARs and CREB phosphorylation via the extracellular signal-
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regulated kinase (ERK) signaling pathway. Our lab reported that PregS at physiologically 
relevant concentration enhanced CREB phosphorylation in rat cortical neurons in primary 
culture, an effect that was dependent on activation of synaptic NMDARs (Smith et al., 
2014). Studies in insulinoma cells also revealed that PregS increases CREB 
phosphorylation (Muller et al., 2011).  
 
2. bZIP transcription factors  
 Studies by Gerald Thiel’s group have focused on the action of PregS via the 
TRMP3 channel and its activation of a signal cascade that leads to an upregulation of gene 
transcription. They have shown that in insulinoma cells PregS increases AP-1 regulated 
gene transcription and the expression of the basic region leucine zipper transcription factors 
c-Fos and c-Jun, which are components of the AP-1 transcriptional complex (Mayer et al., 
2011; Müller et al., 2011).  Their most recent study revealed that the bZIP proteins c-Jun, 
ATF2 and TCFs (ternary complex factor) are essential in order to induce transcription of 
AP-1 regulated genes after PregS stimulation. They also showed that this effect was 
dependent on MAP kinase and a sustained increase in intracellular Ca2+ (Lesch et al., 
2015).  
 
e. Studies of PregS using animal models 
 Systemic or intracerebral administration of PregS has been shown to improve 
memory performance in a large number of studies using rodents. Early studies by Flood et 
al. (1992, 1995) demonstrated that mice that were trained in foot-shock active avoidance 
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task showed enhanced post-training memory processes after intracerebral administration 
of PregS and that PregS was most potent compared to other tested steroids. Another study 
reported that the spatial memory performance of aged rats assessed using the Morris water 
maze and Y-maze was correlated with endogenous PregS levels in the hippocampus - 
higher memory performance had the higher PregS levels. The same relationship was not 
observed in other brain regions, such as the amygdala, prefrontal cortex, parietal cortex 
and striatum. Subsequent administration of exogenous PregS improved the memory 
performance in the impaired rats, suggesting that PregS is involved in the maintenance of 
cognitive performance (Vallee et al., 1997). Darnaudery et al. (2000, 2002) found that 
PregS enhances memory processes and prevents amnesia by inhibiting GABAergic 
afferents to basal forebrain cholinergic neurons. This leads to the activation of cholinergic 
circuits underlying cognitive functions and in an enhanced acetylcholine release within the 
cerebral cortex, amygdala, and hippocampus. Our lab demonstrated that using in vivo 
microdialysis 10 pM PregS induced an increase in extracellular dopamine in striatum via a 
NMDAR dependent mechanism (Sadri-Vakili, 2008). Administration of PregS to APP/PS1 
transgenic mice, which is a mouse model for Alzheimer disease, protected the survival and 
maturation of newborn neurons, as well as improved their performance in a spatial memory 
task (Xu et al., 2012). Mice that were given intracerebroventricular injections of β-amyloid 
25-35 peptide (Aβ (25-35)) showed a decline in spatial cognition and the loss of 50% of 
pyramidal neurons in the CA1 region. However, PregS was able to reduce the spatial deficit 
and death of pyramidal neurons in Aβ (25-35)-mice. The investigators also reported that 
the sigma-1 receptor antagonist and α7nAChR antagonist were able to inhibit the protective 
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effects of PregS implicating the involvement of sigma-1 and α7nACh receptor 
inneuroprotection mediated by PregS (Yang et al., 2012). In a different study, however, it 
was found that bilateral injections of PregS into the hippocampaus impaired passive 
avoidance retention and rats displayed anxiogenic-like behavior based on the open field 
test (Martín-García and Pallarés, 2008). In a more recent study, PregS was reported to 
improve the spatial orientation-acquisition and object discrimination in the Can test, a non-
aversive spatial/visual task (Plescia et al. 2014). In addition, in-vivo electrophysiological 
recordings in the same animals correlated with the behavioral task performance showing 
that PregS potentiated the neuronal activity in the hippocampus and perirhinal cortex.  
PREG, the unsulfated form of PregS, was found to be involved in type-1 cannabinoid 
receptor mediated signaling when administration of tetrahydrocannabinol (THC) increased 
levels of PREG in the frontal cortex, nucleus accumbens, striatum, and other brain regions 
of rats, an effect that was blocked by a type-1 cannabinoid receptor antagonist (Vallée et 
al. 2014).  
 
 
f. Clinical studies of PREG and PregS  
1. Endogenous PREG and PregS as biomarkers for neurological and psychiatric 
disorders 
 
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder and 
the most common cause of dementia, characterized by memory loss, impairments in 
activities of daily living, language, attention and reasoning. Studies have identified several 
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cardinal pathological features of AD, which include plaques (beta-amyloid aggregations), 
neurofibrillary tangles (tau), loss of connections among brain cells responsible for memory, 
learning and communication, inflammation, and cell death leading to tissue shrinkage 
(Citron, 2010; Huang and Mucke, 2012). About 5 million individuals are affected by 
dementia in the USA, making it the sixth leading cause of death. The prevalence of AD 
increases with age with close to 10% of individuals over the age of 70 experiencing 
significant memory loss and more than half of these individuals diagnosed with AD. The 
cost of AD is $91 billion per year for Medicare and $21 billion for Medicaid, while the 
total cost is estimated to be $148 billion per year. AD can be hereditary – about 25% of 
AD cases are familial, of which approximately 95% is late onset (age >60-65 years) and 
5% is early onset (Citron, 2010; Bird, 2014). Current Food and Drug Administration (FDA) 
approved drug treatments for AD include acetylcholine esterase inhibitors to increase the 
levels of acetylcholine (donepezil, galantamine, rivastigmine and tacrine) and NMDAR 
inhibitors to prevent excessive neuronal stimulation (memantine). Ongoing clinical trials 
are focused on reducing amyloid beta production or enhancing clearance by using gamma 
secretase inhibitors or modulators, drugs that induce metal-protein interaction (reduce 
metals that catalyze amyloid beta aggregation), or antibody-based immunotherapy 
(Gauthier and Schelten, 2009; Huang and Mucke, 2012). 
Preclinical studies in rodents have shown that endogenous PregS is neuroprotective 
and exogenous PregS improves cognitive processes, such as learning and memory, and 
have explored the possibility of using PREG or PregS as a therapeutic for disorders in 
which cognitive impairment is observed. Early studies have reported that levels of PREG 
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and PregS in the blood plasma decreases with age in healthy humans (Schumacher et al., 
2003). Therefore, the question arose whether the levels of PregS correlated with impaired 
memory in humans afflicted with AD. Weill-Engerer et al. (2002) studied a possible 
neuroprotective function of PregS and other neurosteroids by assaying their levels in brain 
regions of AD patients. They found that decreased levels of neurosteroids measured in AD 
patients negatively correlated with levels of beta-amyloid peptide and the phosphorylated 
tau protein. The same group led a clinical trial testing PregS as a potential early biological 
marker of memory loss observed in AD (Weill-Engerer, 2009).  
 
2. PREG as an adjunctive treatment in Schizophrenia  
 Schizophrenia is a chronic and debilitating psychiatric disorder affecting 1% of the 
US population. The symptoms are categorized into three groups – positive symptoms, 
negative symptoms, and cognitive symptoms. Positive symptoms include hallucinations, 
delusions, and lack of insight. Negative symptoms encompass the loss of will or drive, loss 
of pleasure, flattening of affect, and social withdrawal. Poor executive functioning, lack of 
attention and impairments in working memory are typical cognitive symptoms (NIHM, 
2009). A plethora of genetic and environmental factors have been postulated to contribute 
to the development of schizophrenia. Clinical studies have shown that administration of 
dopamine releasing drugs, such as methamphetamine, and phencyclidine, an NMDAR 
antagonist,displayed schizophrenia-like symptoms in humans, leading to the proposal of 
the dopamine and glutamine hypothesis, respectively (Javitt, 2007). The dopamine 2 (D2) 
receptor has been the target for drug development., where chlorpromazine was the first 
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typical anti-psychotic drug, and later clozapine became the first atypical anti-psychotic 
drug.The second generation of atypical anti-psychotic drugs have similar effects as the first 
generation but do not possess the extrapyramidal effects of the first-generation drugs. 
However, these drugs have only proven to be successful in treating psychosis (positive 
symptoms), while being ineffective in regards to negative and cognitive symptoms 
(Freedman, 2003; Miyamoto et al., 2012).    
Clozapine was shown to increase PREG in the hippocampus of rodents (Marx et 
al., 2006). In addition, PregS has been shown to positively modulate NMDA receptors.  
Therefore, to test whether PregS could rescue the hypothesized NMDAR hypofunction in 
schizophrenia, a proof-of-concept, double-blind, placebo-controlled clinical trial 
administrating PREG to schizophrenic patients for eight weeks was conducted (Marx et 
al., 2009). The investigators found that patients receiving PREG scored better on cognitive 
tests, which correlated with increased plasma levels of PregS, allopregnanolone and PREG, 
compared with patients receiving placebo. Another group recently reported that PREG 
ameliorated the visual attention deficit in recent-onset schizophrenia and schizoaffective 
disorder (Kreinin et al., 2014).  
An understanding of the mechanism of action of PregS can be valuable for drug 
design and therapeutic intervention aimed at the treatment of psychiatric and neurological 
disorders, wherein glutamatergic neurotransmission is impaired (Weill-Engerer, 2009). 
The enzymes that synthesize and break down PregS and sulfatases that convert PregS to 
PREG are present in the neural tissue of humans and rats (reviewed in Gibbs et al., 2006 
and Hartneck, 2013). Studies have shown that dysregulation of neurosteroid synthesis is 
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implicated in the pathogenesis of several psychiatric and neurological disorders (Zorumski 
et al, 2000; Belleli et al., 2005).  
 
2. Synaptic and structural plasticity  
a. Excitatory synaptic neurotransmission              
1. Long-term potentiation and long-term depression 
  Synaptic plasticity refers to functional and structural changes in synaptic efficacy. 
This includes alterations induced by specific patterns of activity, for example, high-
frequency stimulation of presynaptic afferents in the hippocampus results in both short- 
and long-term changes in synaptic efficacy. The short-term changes include distinct 
patterns of short-term plasticity, such as facilitation and augmentation, which are found in 
presynaptic terminals, involve processes that are Ca2+-dependent, and have a time course 
of less than a few seconds (Thomson, 2000). Post-tetanic potentiation (PTP) lasts a few 
min after the high-frequency stimulation and is another form of short-term plasticity 
(Fioravante & Regehr, 2011). Long-term potentiation (LTP) is a long-lasting increase in 
synaptic strength that is observed following PTP and can last as long as hours, days, weeks, 
or months. LTP is regarded as a potential mechanism for long-term memory (Bliss and 
Collingridge, 1993, Luesher and Malenka, 2012). Its induction involves the coincident 
activity of pre-and postsynaptic neurons. The postsynaptic neuron has to be depolarized 
when glutamate is released from presynaptic terminals to allow the removal of the Mg2+ 
block of the NMDARs. Ca2+ enters the postsynaptic neuron via NMDARs and/or VGCCs 
resulting in activation of intracellular Ca2+ stores and a cascade of intracellular events, 
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including the shuttling of AMPA receptors to the surface membrane and the observed 
increase in synaptic activity (Lledo et al., 1994; Malenka, 1994). NMDA-receptor 
dependent LTP is an associative form of plasticity famously regarded as Hebbian learning 
that requires the correlated activity of two interacting neurons to cause synaptic 
strengthening (Luesher and Malenka, 2012; Malenka and Bear, 2004). Long-term 
depression (LTD) is another form of long-lasting synaptic plasticity, and, as its name 
suggests, is characterized by a long-lasting decrease in synaptic strength (Mulkey and 
Malenka, 1992). It is induced by prolonged periods of low frequency stimulation. LTD is 
a result of decrease in postsynaptic receptor density but also could be due to reduction in 
presynaptic glutamate release. It is believed that LTD results in the weakening of synapses, 
which allows LTP to increase synaptic strength if stimulated. This avoids synapses maxing 
out their level of efficiency, which would inhibit the encoding of new information. Thus, 
similar to LTP, LTD has been shown to be a fundamental mechanism in learning and 
memory (Purves, 2008; Mulkey and Malenka, 1992,Malenka, 1994).  
 
2. Glutamate release 
  The strength of synaptic connection is dependent on at least three elementary 
factors: the number and size of synaptic contacts, the amplitude and duration of the 
postsynaptic depolarization, determined by the  the number of neurotransmitter released 
from a single synaptic vesicle, and the release probability (Branco and Staras, 2009). The 
release probability is important in regards to the pattern of neurotransmitter release and is 
determined by the number of release-ready vesicles, the Ca2+ concentration in the 
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presynaptic terminal, and the molecular coupling between Ca2+ and vesicle fusion. Factors 
such as Ca2+ buffering, affinity of Ca2+ binding sites, differential expression of the Ca2+ 
sensor, synaptotagmin, and characteristics of the action potential invading the presynaptic 
terminal can modulate the release probability. When two stimuli of equivalent strength are 
administered to a presynaptic neuron in close succession, the second postsynaptic response 
is typically higher in amplitude than the first. This is due to the build-up of the residual 
Ca2+ in the presynaptic terminal (evoked by the first stimulus), which will cause an 
increased release probability on the second stimulation. As a result, a greater amount of 
neurotransmitter is released and a larger postsynaptic response is observed. This 
phenomenon is called facilitation. On the other hand, if there is a high release probability 
of a presynaptic cell, most of the available neurotransmitter will be released upon the first 
stimulation, resulting in a smaller postsynaptic response when stimulated for the second 
time (depression) (Branco and Staras, 2009; Thomson, 2000).  
 
3. Glutamate receptors 
  Glutamate is the major excitatory neurotransmitter in the CNS and is a ligand for 
NMDA,AMPA, and Kainate receptors (ionotropic receptors) and mGluR receptors 
(metabotropic receptors) . NMDA and AMPA receptors have been shown to play an 
important role during development, synaptic plasticity and disease pathologies in the CNS 
(McBain and Mayer, 1994; Traynelis et al., 2000).  AMPA receptors (AMPAR) mediate 
the majority of fast synaptic neurotransmission. They are composed of variable 
distributions of four subunits (GluA1-GluA4). Similar to other ionotropic glutamate 
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receptors, GluA subunits have an extracellular N-terminus and an intracellular C-terminus, 
where the S1 and S2 region within the N-terminus contains the ligand binding site. The 
subunit contains three transmembrane (TM) segments and a loop (TMII), which is believed 
to be the ion channel pore-forming region.  GluA subunits have two splice variants, named 
flip and flop. Native AMPARs are not permeable to Ca2+. However, transcriptional editing 
of GluA2 mRNA by changing the positively charged arginine (R) to the neutral glutamine 
(Q) in the TMII region affects the Ca2+permeablity of recombinant AMPARs. This RNA 
site is known as the Q/R editing site. GluA2(Q) is calcium permeable, while GluA2(R) is 
not. Most of the GluA2 subunit expressed in the CNS is in the GluA2(R) form and 
nonedited GluA2(Q) are retained in the ER (Jonas and Burnashev, 1995; Shepherd and 
Hughanir, 2007; Luescher and Malenka, 2012).   
Along with NMDARs, AMPARs are the major ionotropic glutamate receptors 
involved in LTP and LTD. After the exocytosis of glutamate from synaptic vesicles located 
in the presynaptic terminal, glutamate will diffuse across the synaptic cleft towards the 
postsynaptic neuron. At the postsynaptic membrane, it binds to AMPARs resulting in the 
opening of the ion channel and allowing Na+ to flow into the cell, which results in 
depolarization. At resting membrane potential, the NMDAR pore is blocked by Mg2+, 
which prevents any flow of ions. After the removal of the Mg2+ block upon depolarization 
and glutamate binding to the NMDAR, the channel opens and Ca2+, Na+ and K+ can pass 
through into the cell. Due to the influx of Ca2+, the intracellular Ca2+ will reach a threshold 
that initiates signal transduction pathways that eventually lead to LTP or LTD (Luescher 
and Malenka, 2012; Henley and Wilkinson, 2013).  
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4. AMPA receptor trafficking 
LTP is triggered by strong activity of the presynaptic neuron paired with large 
depolarization of the postsynaptic neuron, leading to an increase in intracellular Ca2+. This 
activates calcium/calmodulin-dependent kinase II (CAMKII) and other important kinases, 
which phosphorylate a number of proteins, most importantly AMPARs themselves. 
Phosphorylation of two sites on the GluA1 subunit, serine 831 (S831) and serine 845 
(S845), has been shown to potentiate AMPAR ion channel function (Lee et al., 2003). LTP 
is associated with an increased phosphorylation at S831, while GluA1 phosphorylated at 
S845 leads to receptors being trafficked specifically to extrasynaptic sites (Oh et al., 2005). 
Synaptic activity can then lead to the movement of those receptors laterally into the 
synapse. S831 is phosphorylated by CaMKII and protein kinase C (PKC), while S845 is 
phosphorylated by c-AMP dependent protein kinase A (PKA).  
 AMPARs are inserted into the plasma membrane via an activity-dependent 
mechanism.  When LTP is induced, an increase in the number of synaptic AMPAR is 
mediated via insertion of new AMPARs into the plasma membrane and/or lateral diffusion 
of AMPARs within the membrane to the synapse. For LTD, the opposite occurs, AMPAR 
diffuse away from the synapse or receptors undergo endocytosis. AMPARs assemble in 
the ER as dimers, which then come together to form dimers of dimers to make a tetramer. 
Synaptic AMPARs are mostly combinations of GluA1 and GluA2. Transmembrane 
AMPAR regulatory proteins (TARPs) regulate AMPAR folding and export of AMPARs 
from the ER. The intracellular c-terminal domain (tails) of the GluA subunits are important 
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for trafficking and can either be long or short-tailed. Long-tailed GluA subunits are 
trafficked faster than short-tailed and their trafficking profile predominates in a heteromeric 
subunit combination. GluA1 is long-tailed, while GluA2 is short-tailed, therefore, GluA1/2 
subunit combinations have the trafficking properties of GluA1. The GluA1 subunit will 
mask the ER retention signal of the GluA2 allowing fast receptor trafficking from the ER 
to the plasma membrane. In LTD, less depolarization occurs and a lower amount of Ca2+ 
enters the cell via the NMDAR, leading to the activation of phosphatases, which 
dephosphorylate AMPARs resulting in their endocytosis (Malenka, 1994; Luescher and 
Malenka, 2012; Henley and Wilkinson, 2013).  
 
b. CREB phosphorylation 
  To maintain the increase in synaptic strength, protein synthesis needs to be induced. 
The transcription factor CREB is phosphorylated in a rapid Ca2+-dependent manner by 
stimuli that induce LTP, thereby, resulting in the transcription of genes to promote synaptic 
plasticity (Baudry and Davis, 1997; Anderson, 2007; Collingridge et al., 2010). 
Phosphorylated CREB at serine 133 (S133) binds to the transcription coactivator CREB-
binding protein (CBP) and interacts with the DNA sequence called CRE, resulting in 
activity-dependent CRE-mediated transcription (Chrivia et al., 1993). Studies have shown 
that when CREB function is repressed, consolidation of long-term memory is impaired 
(Kida et al., 2002; Pittenger et al., 2002). It was also demonstrated that levels of 
phosphorylated CREB increases with consolidation of spatial memory in the hippocampus 
in rodents (Porte et al., 2008; Sung et al., 2008).  
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c. Dendritic spines 
Spines are protrusions that are present on dendrites and contain actin, a contractile 
molecule that binds to a family of adaptor and linking molecules and localizes them to the 
postsynaptic density and its associated receptor molecules. The actin cytoskeleton plays an 
important function with regard to formation, elimination, motility, stability, size and shape 
of dendritic spines (Hotulainen and Hoogenraad, 2010; Segal, 2005). Spines exist in a 
variety of sizes and shapes and their lengths and volume can range from 0.5 to 2 µm and 
0.01 to 0.8 µm3, respectively (Hering and Sheng, 2001). Studies using electron microscopy 
have observed roughly three categories of spines based on their morphology:  thin spines 
(thin, filopodia-like protrusions), stubby spines (short spines without a well-defined spine 
neck) and mushroom spines (spines with a large bulbous head; Bourne and Harris, 2008).  
Dendritic spines are sites of glutamatergic excitatory input and their morphology 
can change in response to synaptic activity. It has been reported that increases in 
intracellular Ca2+ can lead to an extension or shrinkage of the same spine depending on the 
type of stimulation.  (Segal et al., 2000). It has been shown that spine associated synapses 
that undergo LTP enlarge, indicating that long-term plasticity also induces structural 
changes (Bourne and Harris, 2008). In addition to increasing in size, new spines can form 
within min after LTP induction. Conversely, LTD can lead to spine shrinkage or complete 
disappearance of spines. It is therefore not surprising that in AD, a correlation between loss 
of dendritic spines and synapses with cognitive decline has been observed (Palop et al., 
2006).  
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Several lines of evidence support the hypothesis that the neuroactive steroid PregS is 
involved in synaptic plasticity. We hypothesized that low pM concentrations of PregS might 
potentiate molecular events underlying synaptic plasticity. The proposed research study will 
support the hypothesis that PregS is an endogenous modulator of neurotransmission. The goals of 
my research are: (1) to determine the physiological relevance of the high affinity PregS-induced 
Ca2+ release and (2) to relate its role to synaptic plasticity, allowing me to determine how PregS 
might be implicated in memory and learning.  
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Chapter 2 
Picomolar concentrations of pregnenolone sulfate increases synaptic GluA1 surface 
expression in hippocampal neurons 
Abstract 
Neuroactive steroids are produced de novo in the central nervous system and have 
been shown to regulate neuronal excitability and synaptic plasticity. Increasing evidence 
suggests that neurosteroids and neuroactive steroids such as pregnenolone and its 
metabolite pregnenolone sulfate (PregS) are implicated in the pathophysiology of 
neuropsychiatric disorders such as schizophrenia.  We recently reported a novel high 
affinity response to PregS (EC50 = 2 pM) that results in increased intracellular Ca
2+ and 
CREB activation in cultured rat cortical neurons. Here, we report that a 10 min treatment 
with 50 pM PregS increases surface expression of the glutamate receptor subunit, GluA1 
and increases colocalization of GluA1 with the postsynaptic density protein PSD95 and the 
presynaptic vesicular glutamate transporter 1 (VGlut1) in hippocampal neurons. Consistent 
with an increase in synaptic/surface GluA1, PregS increases phosphorylation of GluA1 at 
serine 831 (S831) and serine 845 (S845), which is dependent on CAMKII and PKA 
activation, respectively. Whole cell recordings of primary rat hippocampal neurons 
revealed that 50 pM PregS increases the frequency of sEPSCs, suggesting an increase in 
glutamate release from presynaptic terminals and/or generation of new synapses. 
Microtubule-associated protein 2 (MAP2) immunostaining and live imaging of enhanced 
green fluorescent protein (GFP)-transfected hippocampal neurons show that a 10 min 
exposure to 50 pM PregS does not change dendritic spine density. The results indicate that 
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PregS acts within the physiological range of endogenous concentrations to recruit AMPA 
receptors to surface/postsynaptic sites and increase glutamate release, thereby inducing 
synaptic plasticity, while not affecting structural plasticity.   
 
Introduction  
The central nervous system can take up steroids from the blood and also synthesize 
steroids de novo from cholesterol. In addition to the genomic effects of neurosteroids via 
steroid receptors, steroids also modulate the function of neurotransmitter receptors, leading 
to the term “neuroactive steroids” (Baulieu et al, 1998).  Several lines of evidence from 
animal models of disease and basic studies suggest that neuroactive steroids can regulate 
neurotransmission. Steroid hormones have been shown to increase neuronal survival, 
induce neuritic growth and synapse formation during the early stages of development, and 
play an important role in synaptic plasticity in the adult (Charalampopoulos et al., 2008, 
Kretz et al, 2004). Neuroactive steroids are involved in maintaining the balance between 
excitatory and inhibitory neurotransmission by modulating glutamate receptors and 
GABAARs, respectively. Neuroactive steroids include PREG and DHEA, their sulfates 
such as PregS and DHEAS. PregS is synthesized via the sulfation of PREG, catalyzed by 
sulfotransferases, which transfer a sulfonate group (SO3
-) from 3’-phosphoadenosine-5’-
phosphosulfate to the hydroxyl group of PREG (Schumacher et al., 2008, Gibbs et al., 
2006). PregS modulates fast excitatory synaptic transmission by potentiating NMDAR 
activity. PregS is a negative modulator of GABAARs and AMPARs with an IC50 of 7.2 µM 
and 43 µM, respectively, and a positive modulator of NMDARs with an EC50 of 33 µM. 
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PREG (which lacks a C3-sulfate group) is inactive at both GABAARs and NMDARs 
(Majewska and Schwartz, 1987; Wu et al., 1991; Yaghoubi et al., 1998, reviewed by Gibbs 
and Farb, 2000). PregS also activates TRPM3 receptors in primary cultured pancreatic β-
cells with EC50 of 27 µM (Wagner et al., 2008; Mayer et al., 2011). Systemic or 
intracerebral administration of PregS improves memory performance in rodents, and a 
correlation of high PregS levels and amelioration of memory deficits has been observed in 
rodents and humans (Flood et al., 1995, Vallee et al., 1997, Weill-Engerer et al., 2002, 
Schumacher et al., 2008, Xu et al., 2012, Plescia et al., 2014). PregS has been shown to 
enhance LTP by acting on NMDARs, L-type Ca2+channels, sigma receptors, and α7 
nicotinic acetylcholine receptors in the hippocampus (Sliwinski et al., 2004 , Sabeti et al., 
2007, Chen et al., 2007, Chen et al., 2005, Mameli et al., 2005). Recently, it has been shown 
that PregS enhances the insertion of NMDARs into plasma membrane via a G protein–
coupled and Ca2+-dependent mechanism independent of NMDAR activation (Kostakis and 
Smith et al., 2013). 
A great deal of debate in the neurosteroid research community has focused on the 
actual levels of neurosteroids in the brain and the use of the appropriate detection 
methodology (reviewed by Gibbs et al., 2006 and Schumacher et al., 2008). The most 
recent study using LC-ESI-MS-MS showed that PregS is present in the rat hippocampus at 
maximum bulk concentrations of 26 nM (Rustichelli et al., 2013). Since the effects of 
PregS on LTP occur at nanomolar to micromolar concentrations, questions arise about the 
physiological significance of the observed effects. Recently, we have demonstrated a 
novel, high affinity neuromodulatory effect of PregS at physiological concentrations. 
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Picomolar PregS stimulates intracellular Ca2+ increase and promotes CREB 
phosphorylation in rat cultured cortical cells (Smith et al., 2014a). An increase in 
intracellular Ca2+ in the postsynaptic neuron is a critical requirement for the induction of 
bidirectional synaptic plasticity (LTP or LTD). These observations, taken together with the 
high affinity effect of PregS studied in our lab and the plethora of animal studies showing 
the memory-enhancing effects of PregS, suggest that endogenous PregS could be involved 
in processes related to modulating neurotransmission, which underlies the induction of 
neuroplasticity. An understanding of the mechanism of action of PregS can be valuable for 
drug design and therapeutic intervention aimed at the treatment of psychiatric and 
neurological disorders in which glutamatergic neurotransmission is impaired (Smith et al, 
2014b). Therefore, we sought to determine the functional role, if any, of pM PregS in the 
central nervous system. We determined whether pM PregS changes the distribution of 
proteins implicated in synaptic plasticity (GluA1, VGlut1, and PSD95), glutamate 
receptor-mediated responses, dendritic spine density and/or morphology of primary 
hippocampal neurons in cell culture.  
Brief or acute exposure to 50 pM PregS for 10 min increases surface GluA1 and 
colocalization of GluA1 with PSD95 and VGlut1, suggesting increased surface and 
synaptic recruitment of AMPARs. To probe the molecular mechanism by which PregS 
mediates the increase in GluA1, we assessed phosphorylation of GluA1 at S831 and S845 
residues and observed that PregS increased phosphorylation of both S831 and S845, which 
is dependent on CAMKII and PKA activation, respectively. PregS increased the frequency 
of sEPSCs, suggesting that PregS increases presynaptic glutamate release and/or activates 
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silent synapses. Consistent with our previous work (Smith et al., 2014a), we show that the 
observed effects of PregS are contingent upon synaptic NMDAR and L-type Ca2+ channel 
activity. The results provide strong support for the hypothesis that PregS at physiologically 
relevant concentrations promotes molecular events that underlie synaptic plasticity. 
 
Materials and Methods 
Cell culture: Cortical and hippocampal cultures were prepared from E18 Sprague 
Dawley rats (Charles River Laboratories). Cortical cultures were prepared as described in 
Smith et al. (2014a). Dissected hippocampi were dissociated with 2.5 % trypsin and 0.1 % 
DNAse. Cells were suspended in neurobasal media containing 10 % horse serum, 1 % 
glutamine and 1 % pen/strep and plated on poly-l-lysine (1 mg/ml) coated glass coverslips 
at a cell density of 75,000 cells per well. One hour post-plating, the media was completely 
changed to neurobasal media containing 1 % B27, 1 % glutamine, and 1 % pen/strep. 
Cultures were maintained until use with partial media changes every 3-4 days. 
Immunocytochemistry: Cultured DIV21 hippocampal neurons were treated for 10 
min with vehicle (VEH) (0.05 % DMSO) and 50 pM PregS in HEPES solution (in mM: 
137 NaCl, 5 KCl, 3 CaCl2, 10 HEPES, 10 glucose, pH = 7.3). After treatment, cells were 
washed once with 1X PBS before they were fixed. C-GluA1/PSD95:  Cells were fixed with 
4 % PFA/4 % sucrose in 1X PBS for 2 min at 37 °C followed by 10 min with ice-cold 
methanol. Cells were permeabilized with 0.25 % Triton X-100 for 15 min and blocked with 
5 % donkey serum and 2 % goat serum for 1 hr at room temperature (RT). Then cells were 
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incubated with polyclonal rabbit anti-C-GluA1 antibody (1:200; Milipore) and mouse 
monoclonal anti-PSD5 antibody (1:200; Abcam)  in 5 % donkey serum overnight at 4 °C, 
followed by 1 hr incubation with Alexafluor 488 donkey anti-rabbit (1:1000; Invitrogen) 
and Alexafluor 647 goat anti-mouse (1:500; Invitrogen). N-GluA1/VGlut1: Cells were 
fixed with 4 % PFA/4 % sucrose in 1X PBS for 10 min at 4 °C and blocked with 8 % BSA 
and 5 % goat serum for surface GluA1 for 1 hr at RT. Cells were incubated with 
monoclonal mouse anti-N-GluA1 for 2 hrs in 5% goat serum at RT, followed by one-hour 
incubation with Alexafluor 488 goat anti-mouse (1:500; Invitrogen). After postfixing for 
15 min with 4 % PFA, permeabilized with 0.25 % Triton X-100, and blocked with 5% goat 
serum for 1 hr at RT, cells were incubated O/N at 4 °C with guinea pig polyclonal anti- 
VGlut1 antibody (1:4000; Millipore), followed by a 1 hr  incubation with Alexafluor 647 
goat anti- guinea pig (1:1000; Invitrogen). Coverslips were mounted onto glass slides using 
Gold Anti-fade with DAPI mounting reagent (Invitrogen). MAP2: Cultured hippocampal 
neurons were treated for 10 min with VEH (0.05 % DMSO) and 50 pM PregS in HEPES 
solution. After treatment, cells were washed once with 1X PBS before they were fixed. 
Cells were fixed with 4 % PFA in 1X PBS for 1 hr at RT, permeabilized in 0.25 % Triton 
X-100 for 15 min, blocked with 4 % normal goat serum for 1 hr at RT and incubated with 
mouse monoclonal anti-MAP2 antibody (1:2000; Sigma Aldrich) overnight at 4 °C, 
followed by a 1 hr incubation with Alexafluor 488 goat anti-mouse (1:500; Invitrogen). 
Enhanced GFP (eGFP): Cultured hippocampal neurons were treated for 10 min with VEH 
or 50 pM PregS in HEPES solution. After treatment, cells were washed once with 1X PBS 
before they were fixed. Cells were fixed with 4 % PFA in 1X PBS for 1 hr at RT, 
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permeabilized in 0.25 % Triton X-100 for 15 min, blocked with 5 % normal goat serum for 
1 hr at RT and incubated with chicken monoclonal anti-GFP antibody (1:1000; Aves) for 
2 hrs at RT, followed by 1 hr incubation with Alexafluor 488 goat anti-chicken (1:5000; 
Invitrogen).  
eGFP transfection: Hippocampal cultures were prepared as described above. Cells 
were transfected using the Amaxa Basic Neuron SCN Nucleofector kit and the 
Nucleofector device (Lonza) with farnesylated-eGFP cDNA, according to the Lonza 
protocol. Per 100,000 cells 0.5 µg of DNA was used.  After plating transfected cells on 
confocal dishes, 50,000 nontransfected cells were added to each dish. Cultures were 
maintained until use. Partial media was changed three days after plating and then once a 
week until use.  
Confocal Ca2+ imaging: Cells were incubated for 30 min at 37°C with a cell 
membrane-permeable Ca2+ indicator Fluo-4 acetoxymethyl ester (Invitrogen, CA). 
Changes in [Ca2+] fluorescence intensity (F) was measured at excitation wavelength of 
488nm and emission of 505-735nm, and normalized to initial intensity (F/F0, arbitrary 
units) for each region of interest. The cells were imaged in real time at room temperature 
in extracellular buffer (in mM) NaCl 137, KCl 5, CaCl2 3, glucose 25, HEPES 10.  A Zeiss 
Laser Scanning Microscope (LSM) was used with 40x water immersion objective, and 
images were captured at 1 frame per 1.57 sec. Regions of interest were selected for 
morphologically identified cells using Zeiss Axiovert software to determine changes in 
fluorescence intensity with a dynamic range of 0-255. The effect of drug application (∆F/F) 
was determined as a difference between (F/F0) before and during the peak (F/F0) after drug 
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application.  
Immunoflurorescence imaging: Fluorescent images of GluA1, VGlut1, PSD95 and 
MAP2 stained cells were obtained by a Nikon deconvolution wide-field epiflourescence 
microscope using a 60X or 100X oil objective at FITC and/or 647 channels. The same 
exposure time was used for all the coverslips stained with the same antibody. At least 10 
fields were imaged for each coverslip. Confocal images of eGFP-transfected cells were 
acquired using a Zeiss LSM 710 laser scanning confocal microscope with a 100X oil 
immersion objective lens at a resolution of 0.042 x 0.042 x 0.38 µm per voxel.  
Fluorescence was excited using 488 nm light, and acquired spine images were deconvolved 
using AutoQuant (MediaCybernetics).  
Image Analysis: Puncta were isolated by thresholding using the average 
background intensity multiplied by 2 for C-GluA1, 1.35 for N- GluA1, 1.75 for VGlut1, 
and 1.5 for PSD95 (Lu et al., 2001) and quantified using Image J software (NIH) using a 
custom-made algorithm. Puncta size was limited between 3.3 to 100 pixels (Ippolito and 
Eroglu, 2010). Puncta larger than 100 pixels, likely to be aggregates of smaller puncta, 
were resolved into smaller puncta after thresholding using their background intensity. 
Regions of interest (ROI) were selectecd by two independent investigators (3-5 ROIs per 
image from 7-10 images per treatment group from one independent culture). Colocalization 
analysis was performed via a manual count of the yellow puncta (red and green colocalized 
puncta) per dendritic length by three independent investigators. For C-GluA1 and PSD95, 
only green and red puncta that overlapped by >75 % were included in the analysis. N-
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GluA1 and VGlut1 were consideredclosely apposed to each other  if at least one pixel of 
their fluorescence signals directly overlapped . These close apppositions were considered 
to be putative synapses. Neuron tracing and spine count were performed using 
Neuronstudio software by two independent investigators. Spines of eGFP transfected cells 
were manually counted via Image J software (NIH) by two independent investigators. For 
Ca2+ imaging analysis, the change in fluorescence divided by baseline fluorescence (F/F0) 
was measured by taking the peak value in the 1.5 min recording. Baseline fluorescence was 
determined by averaging over a 5 sec time window immediately before application of drug. 
Western Blot: Hippocampal and cortical DIV21 cultures were treated with 50 pM 
PregS or VEH at 37°C for 10 min. Cells were washed once, scraped and collected in ice 
cold PBS solution supplemented with cOmplete protease inhibitor cocktail and PhosSTOP 
phosphatase inhibitor cocktail (Roche) and 1 mM PMSF). Whole cell extracts were 
prepared in lysis buffer (in mM) Tris-HCl 500, pH 7.4, NaCl 1500, 2.5 % deoxycholic acid, 
10 % NP-40, EDTA 10, PMSF 1, Na3VO4 1, NaF 1, supplemented with cOmplete protease 
and PhosSTOP phosphatase inhibitor cocktails, and processed for Western blot. 
Membranes were blocked with 5 % milk for 1 hr. The membranes were then incubated 
with primary antibodies (1:1000; anti-pCAMKII (Cell Signaling), anti-CAMKII, (Abcam), 
anti-pGluA1 (S831; Millipore), anti-pGluA1 (S845; Cell Signaling), anti-GluA1 
(Millipore)) overnight at 4 °C. After the primary incubation the membranes were washed 
and incubated with a goat anti-rabbit IgG antibody (Santa Cruz Biotechnology) at a dilution 
of 1:2000 in 5 % nonfat dry milk for 1 hr at RT. pGluA1 and GluA1 were normalized to 
the total protein content through a ß-actin Western blot, and then the ratio of 
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phosphorylated protein to total protein was calculated.  
Whole cell patch clamp electrophysiology: Coverslips were mounted on a recording 
chamber filled with extracellular solution (ECS; in mM: 140 NaCl, 10 HEPES, 10 Glucose, 
2.5 KCl, 4 MgCl2, 4 CaCl2, pH = 7.4, osmolarity = 320-335 mmol/kg) at RT. Cells were 
visualized using IR-DIC optics at 40X on a Nikon microscope. Electrodes were filled with 
K-Glu solution (in mM: 110 KGlu, 40 KCl, 5 EGTA, 2 MgCl2, 10 NaHEPES) and their 
resistance ranged from 4 – 6 MΩ. Data acquisition was done with PatchMaster acquisition 
software using an EPC-10 patch clamp amplifier (HEKA Electronics), filtered at 10 kHz. 
Passive membrane properties such as input resistance, resting membrane potential and 
membrane time constant were determined by applying a series of 200 ms current pulses 
(10 pA steps starting from -40 pA to +40 pA). By plotting the current vs voltage data from 
the linear portion of the 200 ms series, we were able to calculate the input resistance from 
the slope of the best fit line and the resting membrane potential from the y-intercept 
(membrane potential in the absence of current injection). We determined action potential 
(AP) properties such as amplitude and threshold by applying a series of 2000 ms 
hyperpolarizing and depolarizing current pulses (40 pA increments, starting from -100 pA 
to 340 pA). A 10 sec current ramp from 0 to 200 pA was used to determine rheobase, which 
is the current required to elicit a single AP. Spontaneous EPSCs were recorded for 2 min 
at -80 mV. Synaptic events were analyzed using MiniAnalysis software (Synaptosoft). The 
automated event detection was used at a threshold of 15 pA, which was followed by 
manually checking for false positives and negatives. The following sEPSC properties were 
determined: frequency, amplitude, rise time, decay time, area (charge transfer), and half-
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width (duration of sEPSC). 
Stock Solutions: PregS, PEHS, PREG (Steraloids), KN62, KN93, KN92, Go6983, 
nifedipine (R&D systems), MK801and bicuculline (Sigma Aldrich) were prepared in 
DMSO. CNQX, PKI-1422, Ro 25-6981, BD1063 (R&D systems) and ifenprodil (Sigma 
Aldrich) were dissolved in water. 
Statistical Analyses: Statistical significance of obtained values was determined using 
Mann Whitney U t-test via GraphPad Prism. Significance is indicated where for VEH vs 
PregS, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, and for VEH or PregS vs 
inhibitor, # p < 0.05. 
 
Results 
PregS treatment increases the frequency of AMPAR-mediated sEPSCs in DIV21 
hippocampal cultures 
 
 Previously, we have shown that 50 pM PregS increases intracellular Ca2+ in Fluo4-
loaded rat DIV7 cortical neurons (Smith et al., 2014a). We confirmed that 50 pM PregS 
also induced Ca2+ influx in rat DIV21 hippocampal neurons (5 independent cultures; Fig. 
2A and 2B). To study the effect of pM PregS on synaptic transmission, we recorded from 
DIV21 hippocampal cells in the whole-cell patch clamp configuration. Recordings were 
obtained at a holding membrane potential of -80 mV in high Mg2+-containing ECS. Under 
these conditions, synaptic events are predominately mediated by AMPARs. Typically, a 
change in frequency of sEPSCs indicates that PregS may modulate spontaneous 
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presynaptic glutamate release or activates silent synapses, while a change in sEPSC 
amplitude signifies that PregS may modulate neurotransmission by acting on postsynaptic 
receptors (Han and Stevens, 2009). Compared to VEH, 10 min, 50 pM PregS-treated cells 
did not elicit a change in mean amplitude of sEPSCs (22.57 ± 2.14 pA versus 28.59 ± 4.30 
pA, p = 0.285, 9 independent cultures, 16 VEH and 15 PregS-treated cells). However, an 
increase in frequency was observed in PregS-treated cells (2.76 ± 0.27 Hz versus 4.49 ± 
0.37 Hz, p < 0.003) (2C). We did not see a change in mean area of sEPSCs with PregS 
treatment. With regard to the kinetic properties of the sEPSCs, rise time, decay time, and 
half-width were unchanged in PregS-treated cells, compared to VEH-treated cells (Table 
2). A series of current steps was applied to determine passive membrane properties (resting 
membrane potential, membrane time constant, and input resistance). No significant 
difference between PregS- and VEH-treated cells was observed. Moreover, no significant 
difference in AP properties (amplitude, threshold, and rheobase) was observed between the 
two groups (Table 1). A 10-min preincubation with 10 µM nifedipine, inhibited the PregS-
induced increase in sEPSC frequency, suggesting the involvement of L-type voltage gated 
Ca2+channels (L-type VGCC) in the effect of PregS on sEPSC frequency (Fig. 3). PREG 
(the unsulfated form of PregS) does not modulate NMDARs (Weaver et al., 2000) and we 
have previously shown that the high-affinity PregS effect on intracellular Ca2+ is structure 
specific (Smith et al., 2014a). We tested the effect of PREG and pregnenolone 
hemisuccinate (PEHS, a synthetic analogue of PregS) on sEPSCs. Frequency and 
amplitude of sEPSCs were unchanged by 50 pM PEHS, 50 pM PREG and 50 fM PregS  
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Fig. 2. 50 pM PregS increases intracellular Ca2+ and frequency of AMPAR-mediated 
sEPSCs in rat DIV21 hippocampal neurons. A. DIV21 hippocampal cells before (0 sec) 
and after (15 sec) application of 50 pM PregS. White arrows point at neurons that 
responded to PregS application. A transient increase in fluorescent calcium indicator 
intensity is indicated with a pseudo color scale. Scale bar, 20 µm. B. Mean fluorescence 
intensity normalized to average initial intensity (F/Fo) for regions of interest imaged every 
1.5 sec for 1.5 min after exposure to 50 pM PregS. Graph represents mean ± SEM. C. 
Representative traces of sEPSCs recorded at a holding potential of -80 mV in the presence 
of VEH or PregS. 20 µM CNQX blocked high amplitude sEPSCs. D. Sample trace of 
sEPSC burst.  
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Table 1. Comparison of Passive Membrane and AP properties of VEH and PregS-
treated hippocampal cells. Compared to VEH-treated cells, PregS did not have a 
significant effect on passive membrane and AP properties (6 independent cultures, 12 VEH 
and 10 PregS-treated cells). Data represent mean ± SEM.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Resting Membrane Potential (mV) (-)52.32  ±  4.393  (-)52.34  ±  5.355 0.817 No
Input Resistance (MΩ)    234.6  ±  23.39 199.2  ±  18.19 0.248 No
Membrane Time Constant (ms) 24.02  ±  2.217 18.93  ±  1.973 0.223 No
Single Spike Ampliude (pA) 57.44  ±  3.332 60.96  ±  4.706 0.921 No
Single Spike Threshold (mV) (-)33.62   ±  3.868 (-)34.84   ±  4.389 0.921 No
Rheobase (pA) 56.34  ±  9.481 53.09  ±  12.33 0.751  No
Action Potential Properties
Statistical significance?p-valueVEH 50 pM PregSIntrinsic Membrane Properties
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Table 2. Quantification of sEPSC properties. sEPSC amplitude, frequency, area, rise 
time, half-width and decay time for VEH and PregS were quanitfied (9 independent 
cultures, 16 VEH and 15 PregS-treated neurons). Data represent mean ± SEM. **p < 0.01 
vs VEH.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Frequency (Hz) 2.76 ± 0.27 4.49 ± 0.37 0.003 Yes **
Amplitude (pA) 22.57 ± 2.14 28.59 ± 4.30 0.285 No
Area (pA/ms) 302.90 ± 46.81 320.80 ± 37.36 0.662 No
Rise time (ms) 2.00 ± 0.24 2.26 ± 2.58 0.463 No
Half-width (ms) 11.85 ± 1.01 13.22 ± 0.96 0.353 No
Decay time (ms) 12.13 ± 0.99 12.34 ± 1.23 1.000 No
sEPSC properties VEH 50 pM PregS p-value Statistical significance?
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Fig. 3. 50pM PregS-induced increase in sEPSC frequency is concentration dependent, 
structure specific and inhibited by 10 µM nifedipine. Quantification of sEPSC 
amplitude and frequency showing structural specificity and concentration dependence of 
PregS-induced increase in sEPSC frequency (3 independent cultures, 9 PregS (50fM), 7 
PREG (50pM) and 9 PEHS (50pM)-treated neurons). DIV21 hippocampal cultures were 
pretreated with 10 µM nifedipine for 10 min before application of VEH or 50 pM PregS 
for 10-15 min (3 independent cultures, 7 Nif- and 8 Nif+PregS-treated neurons). Data 
represent mean ± SEM. **p < 0.01 vs VEH and # p < 0.05 vs PregS.  
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(Fig.3), suggesting that the effect of PregS on sEPSC frequency is structure specific and 
dependent on concentration. Bursts of sEPSCs were not discussed in previous analysis (Li 
et al., 1998). A sample sEPSC burst is shown in Fig.2D. If PregS increases the synaptic 
strength, we might expect PregS to alter burst activity by increasing the number of events, 
maximum amplitude of EPSC events within a burst, duration and/or frequency of bursts. 
We therefore quantified the bursts separately and found that PregS did not have an effect 
on maximum amplitude of EPSC events within a burst, duration of bursts, the number of 
events within a burst, and the frequency of bursts (Table 3). It is important to note that the 
number of events within a burst tend to overlap, making it difficult to clearly resolve them. 
These results indicate that PregS does not modulate synchronized multivesicular 
presynaptic release of glutamate and the postsynaptic response to glutamate. 
 
PregS does not change spine density of primary hippocampal neurons stained with MAP2 
and transfected with eGFP 
Dendritic spines are sites of glutamatergic excitatory input and their morphology 
can change in response to synaptic activity. PregS-mediated increases in intracellular Ca2+ 
and induction of pCREB can lead to changes in spine morphology and/or the generation of 
new spines. Previous studies have shown that 0.1 µg/ml estradiol increases dendritic spine 
density in hippocampal neurons in a manner that is dependent on NMDAR activation and 
increases CREB phosphorylation (Murphy and Segal, 1996 and 1997). Since we observed 
an increase in intracellular Ca2+ in DIV7 cortical neurons in our previous study (Smith et  
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Table 3. Quantification sEPSC burst properties. Quantification of frequency of bursts, 
events within each burst, max amplitude of events within burst,duration of burst, and area 
of burst (9 independent cultures, 16 VEH and 15 PregS-treated neurons). Data represent 
mean ± SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency (Hz) 0.038 ± 0.01 0.06 ± 0.08 0.835 No
Max amplitude (pA) 760.40 ± 233.90 835.60 ± 120.0 0.207 No
Area (pA/ms) 1419 ± 236.90 2023 ± 214.60 0.144 No
Duration (ms) 346.60 ± 33.40 409.60 ± 51.96 0.406 No
Number of events within bursts 7.95 ± 0.85 9.70 ± 1.68 0.479 No
Burst properties VEH 50 pM PregS p-value Statistical significance?
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al., 2014a), we tested the hypothesis that 50 pM PregS will increase dendritic spine number. 
MAP2 immunostaining of primary hippocampal neurons showed that 10 min, 50 pM PregS  
treatment did not affect dendritic spine density in proximal and distal dendrites (3 
independent cultures; Fig. 4C). We used an additional method for visualizing spines by 
transfecting hippocampal neurons with farnesylated eGFP (Fig. 4A) and performed live 
imaging of spines with a confocal microscope at 100X (Fig. 4B). The transfection itself 
did not affect the morphology of neurons, and spine density was comparable to MAP2-
stained cells (10-11 spines/20 µm). During the imaging, cells were incubating in VEH for 
15 min before PregS was added to obtain a final concentration of 50 pM. Qualitative 
analysis of spine density of eGFP-transfected cells revealed that 50 pM PregS did not affect 
the number of spines present on proximal and distal dendrites (4 independent cultures). 
These results demonstrate that acute exposure to pM PregS does not affect structural 
plasticity. 
 
PregS increases the insertion of GluA1-containing AMPA receptors into the synaptic 
membrane 
PregS-induced redistribution of endogenous AMPARs was examined using 
immunofluorescence in DIV21 hippocampal neurons. We probed for surface GluA1 using 
an antibody against the N-terminus of GluA1 (N- GluA1), under nonpermeant conditions, 
followed by staining for VGlut1 (a marker for presynaptic glutamatergic terminals) after 
cell permeabilization (Fig. 5). Changes in the number and size of puncta were assessed 
after a 10 min treatment with VEH or 50 pM PregS (Fig. 5B and C). PregS significantly  
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Fig. 4. 10 min, 50 pM PregS does not change dendritic spine density in DIV21 
hippocampal cultures. A. Representative images of anti-GFP-stained farnesylated eGFP-
transfected cells. Scale bar, 10 µm. B. Time series showing images of eGFP-transfected 
hippocampal dendritic spines after 15 min incubation with VEH followed by 10 min 
treatment with 50 pM PregS. Images were taken with a confocal wide-field microscope at 
100X. Scale bar, 5 μm. C. Quantification of spine density in MAP2-stained cells treated 
with 50 pM PregS for 10 min (3 independent cultures). Data represent mean ± SEM.  
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increased the density and size of N-GluA1 puncta (p < 0.0001 for proximal dendrites, 6 
independent cultures). The density and size of VGlut1 puncta was not affected by PregS, 
suggesting that PregS does not increase the number of putative presynaptic contacts (6 
independent cultures). However, we observed an increase in the number of appositions of 
N-GluA1 puncta to VGlut1 puncta (p = 0.02, 6 independent cultures, Fig. 5D), indicating 
that PregS increases GluA1 localization at postsynaptic sites.  
 We next asked whether the increase in surface GluA1 was dependent on synaptic 
NMDAR activation (Fig. 6). In order to isolate synaptic NMDARs, cultures were treated 
with 15 µM bicuculline methiodide for 15 sec followed by a 1 min treatment with 10 µM 
MK-801. This allows use-dependent block of synaptic NMDARs (Hardingham et al., 
2002). Pretreatment of cultures with MK801/BIC unexpectedly increased basal surface 
GluA1, however, 10 min, 50 pM PregS did not cause a further increase in surface GluA1, 
suggesting that the PregS effect is contingent upon synaptic NMDAR activation. To 
identify if PregS-induced increase of surface GluA1 is GluN2 subtype specific, we co-
applied 1 µM Ro 25-6981 (a GluN2B subtype selective antagonist) with PregS. We found 
that Ro 25-6981 inhibited the increase in surface GluA1. Finally, we tested the involvement 
of sigma 1 receptors (σ1 R) by co-application of 1 µM BD1063 with PregS. BD1063 did 
not inhibit PregS effect. 
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Fig. 5. Surface GluA1 increases in hippocampal neurons after a 10 min exposure to 
50 pM PregS. A. Representative images showing that the density and size of N- GluA1 
puncta increases in proximal dendrites. Puncta density and size are unchanged for VGlut1 
with PregS treatment in proximal dendrites (6 independent cultures). B and C. Quantitative 
analysis of puncta density and size for N-GluA1 and VGlut1 (6 independent cultures). D. 
Quantification of apposition of VGlut1 to N-GluA1 puncta showing that PregS increases 
the number of putative synapses (6 independent cultures).  Scale bar, 5 µm. Data represent 
mean ± SEM. *p < 0.05 vs VEH, ****p < 0.0001 vs VEH. 
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Fig. 6. PregS-induced increase in surface GluA1 is dependent on NR2B-containing 
NMDAR activity. Quantification showing that the increase in surface GluA1 due to PregS 
is inhibited by 1 µM Ro 25-6981 and MK801/BIC. 1 µM BD1063 did not have an effect 
(3 independent cultures for inhibitors, 9 independent cultures for controls). Data represent 
mean ± SEM. **p < 0.01 vs VEH, ****p < 0.0001 vs VEH, # p < 0.05 vs VEH, not 
significant (n.s.) p >0.05. 
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To confirm this observation, after 10 min treatment with VEH or 50 pM PregS, 
neurons were probed with an antibody against the C-terminus of GluA1 (C-GluA1) and 
PSD95, a synaptic marker (Fig. 7). The density and size of C-GluA1 and PSD95 puncta 
did not change, suggesting that protein expression of GluA1 does not increase with 
treatment (Fig. 7B and C). Next, we asked whether 50 pM PregS increases the insertion of 
GluA1-containing AMPARs into the synaptic membrane. Synaptic recruitment of GluA1 
was determined by assessing the colocalization of GluA1 with PSD95. We observed a ~ 
50% increase in colocalization of GluA1 with PSD-95 in proximal dendrites (p = 0.003, 6 
independent cultures, Fig. 7D). These results indicate that PregS stimulation leads to the 
recruitment of AMPARs to the synapse.  
We asked if 50 pM PregS-induced increase in GluA1/PSD95 colocalization is 
contingent upon either L-type VGCC or NMDAR activation.  For this, hippocampal 
neurons were pretreated for 10 min with 10 µM nifedipine or D-AP5. 10 µM nifedipine 
suppressed the observed increase in colocalization of GluA1 with PSD-95 (Fig. 8). 
Pretreatment of cultures with 50 µM D-AP5 unexpectedly increased colocalization. 
Therefore, we investigated the subunit-specific role of NMDARs and synaptic versus 
extrasynaptic NMDARs in PregS-mediated effects.  Co-application of 1 µM Ro 25-6981 
with 50 pM PregS inhibited the increase in colocalization of GluA1 with PSD95. 
Pretreatment with BIC/MK-801 also blocked the increase in colocalization due to PregS, 
while 1 µM BD1063 did not. Taken together, our results suggest that pM PregS increases 
surface expression of synaptic AMPARs via activation of L-type VGCCs and synaptic 
NMDARs, particularly the GluN2B subtype. We previously reported a potential  
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Fig. 7. 10 min, 50 pM PregS treatment enhances GluA1 colocalization with PSD95 in 
DIV21 hippocampal cultures. A. Representative images showing that C-GluA1 and 
PSD95 puncta density and size do not change in proximal dendrites after a 10 min exposure 
to 50 pM PregS (6 independent cultures). However, C-GluA1 colocalization with PSD95 
is increased in proximal dendrites after PregS treatment. B. and C. Quantitative analysis 
of puncta density and size for C-GluA1 and PSD95 (6 independent cultures). D. 
Quantification of C-GluA1 colocalization with PSD95 (6 independent cultures). Scale bar, 
5 µm. Data represent mean ± SEM. **p < 0.01 vs VEH.  
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Fig. 8. PregS-induced increase in GluA1/PSD95 colocalization is dependent on L-type 
Ca2+ channel activity and NMDAR-mediated synaptic activity. A. Quantification 
showing that C-GluA1 colocalization with PSD95 is inhibited by 10 µM nifedipine, 1 µM 
Ro 25-6981, 15 µM bicuculline followed by 10 µM MK801 and 50 µM D-AP5 . 1 µM 
BD1063 did not affect PregS-induced C-GluA1/PSD95 colocalization. (3 independent 
cultures for inhibitors, 9 independent cultures for controls). Data represent mean ± SEM. 
*p < 0.05 vs VEH, ****p < 0.0001 vs VEH, # p < 0.05 vs VEH, not significant (n.s.) p 
>0.05. 
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high-affinity binding site of PregS that is modulated by pM concentrations of ifenprodil, a 
GluN2B antagonist (Smith et al., 2014a). To test if this putative PregS high-affinity binding 
site is involved in the observed increase in surface GluA1, 50 pM PregS was co-applied 
with 250 pM ifenprodil. We found that ifenprodil did not block the increase in surface 
GluA1 and GluA1/PSD95 colocalization (data not shown). PREG (the unsulfated form of 
PregS) does not modulate NMDARs (Weaver et al., 2000) and we have previously shown 
that the high-affinity PregS effect on intracellular Ca2+ is structure specific. We tested the 
effect of PREG and PEHS on GluA1 surface expression and GluA1/PSD95 colocalization 
and found that they had no effect.  In addition, we confirmed that 50 fM PregS did not 
induce an effect, indicating that the concentration range of the PregS effect is similar to 
PregS-induced intracellular Ca2+ increase (Table 4).  
 
PregS increases phosphorylation of GluA1 at S831 and S845 
The phosphorylation status of specific amino acid residues known to be essential 
for surface and synaptic recruitment of AMPARs was evaluated using phospho-specific 
antibodies and Western blotting. Phosphorylation of GluA1 subunit, serine 831 (S831) and 
serine 845 (S845), has been shown to potentiate AMPAR ion channel function (Lee et al., 
2003). LTP is associated with an increased phosphorylation at S831. GluA1 
phosphorylated at S845 leads to receptors being trafficked specifically to extrasynaptic 
sites (Oh et al., 2006). Synaptic activity can then lead to those receptors moving laterally 
into the synapse. S831 is phosphorylated by CaMKII or protein kinase C (PKC), while 
S845 is phosphorylated by PKA. 
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Table 4. Quantification of surface GluA1 and GluA1/PSD95colocalization. 
Quantification indicates that 50 pM PEHS, 50 pM PREG and 50 fM PregS did not increase 
surface GluA1 and GluA1/PSD95 colocalization, respectively, similar to 50 pM PregS (3 
independent cultures). Data represent mean ± SEM. **p < 0.01 vs VEH, ****p < 0.0001 
vs VEH.  
 
  
 
 
 
 
 
 
 
 
 
 
VEH 14.99 ± 0.64 NA NA 2.05 ± 0.23 NA NA
50 pM PregS 19.23 ± 0.70 <0.0001 Yes**** 3.04 ± 0.25 0.002 Yes**
50 fM PregS 14.84 ± 1.01 0.551 No 1.76 ± 0.25 0.762 No
50 pM PEHS 17.91 ± 1.40 0.261 No 1.76 ± 0.18 0.929 No
50 pM Preg  19.17 ± 1.43 0.206 No 1.78 ± 0.13 0.549 No
p-value 
Statistical 
significance 
vs. VEH?
N-GluA1                                              
puncta / 20 µM 
C-GluA1/PSD95                      
colocalized puncta / 20 µM 
p-value
Statistical 
significance 
vs. VEH?
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We asked whether PregS-induced increase in surface GluA1 involves phosphorylation of 
GluA1. As shown in Fig 9A, in PregS-treated DIV21 cortical and hippocampal neurons, 
GluA1 phosphorylation at S831 is elevated (p = 0.0005 and p = 0.04, respectively). PregS 
also increases phosphorylation of S845 in cortical neurons (p = 0.003) and in hippocampal 
neurons (p = 0.05, Fig. 9B). We observed higher variability in levels of phosphorylation 
and low yield in material for Western blot with hippocampal cultures and therefore 
performed most of the subsequent experiments using cortical cultures. We also show that 
50 pM PEHS, 50 pM PREG and 50 fM PregS did not increase S831 and S845 in cortical 
neurons (Fig. 10). These results support the idea that PregS stimulates trafficking of 
AMPARs to the surface via phosphorylation of GluA1.  
 Next, we investigated whether phosphorylation of S831 is mediated via CAMKII 
or PKC activation by using their respective inhibitors (Fig. 11 and 12). Cortical neurons 
were preincubated with 10 µM KN62 (CAMKII inhibitor) or 10 µM Go6983 (a broad 
spectrum PKC inhibitor) before 10 min treatment with VEH or 50 pM PregS. We found 
that KN62 blocked the increase in GluA1 phosphorylation due to 50 pM PregS, while the 
PKC inhibitor did not. We further validated the involvement of CAMKII activation by 
using KN93, an alternative CAMKII inhibitor, and KN92, the inactive analogue of KN93, 
as a control. KN93 showed inhibition of the PregS-induced increase in S831, while KN92 
did not have an effect. These results suggest that PregS-induced phosphorylation of GluA1 
at S831 is dependent on activation of CAMKII. Phosphorylation of S845 is dependent on 
PKA activity and we tested whether we could block PregS-induced phosphorylation 
ofS845 using PKI-1422 amide, a PKA inhibitory peptide. In cortical neurons, we observed 
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that PKI-1422 inhibits the increase in S845 due to PregS, suggesting that PregS acts via 
activation of PKA (Fig. 13). 
 
Discussion  
Multiple studies have shown that PregS acts as a cognitive enhancer and improves 
memory in rodent models (Flood et al., 1995, Vallee et al., 1997, Xu et al., 2012, Plescia 
et al., 2014). Micromolar (µM) concentrations of PregS increases LTP in CA1 pyramidal 
neurons via an σ1 receptor,L-type VGCC, and NMDAR activation-dependent mechanism 
(Sabeti et al., 2007, Sliwinski et al., 2004). Mameli et al. (2005) showed that treatment with 
25 µM PregS induced a delayed potentiation of AMPAR-mediated synaptic currents. 
However, the physiological relevance of these observations remains unclear since PregS is 
not detected at µM concentrations within the brain (reviewed by Smith et al., 2014b). 
Moreover, these studies did not elucidate the specific molecular mechanisms underlying 
the PregS-induced increase in AMPAR surface expression.   
 Previously, we have shown that pM PregS causes a rapid increase in intracellular 
Ca2+ that is dependent on NMDAR and L-Type VGCC activation (Smith et al., 2014a). 
Increase in intracellular Ca2+ fulfills essential requirements for an increase in synaptic 
strength or LTP-like changes (Collingridge et al., 1983, Lynch et al., 1983) and gene 
expression (Collingridge et al., 2004; Bliss and Schoepfer, 2004). It was anticipated that 
the PregS-induced increase in Ca2+ would lead to alterations in presynaptic glutamate 
release and/or postsynaptic changes in glutamate receptors, namely an increase (LTP-like) 
or decrease  
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Fig. 9. 10 min, 50 pM PregS increases the phosphorylation of GluA1 at S831 and S845 
in DIV21 hippocampal and cortical neurons. A. Representative blots and quantitative 
analysis show that pGluA1 (S831) are significantly increased with PregS, compared to 
VEH, in DIV21 hippocampal and cortical neurons (10-14 independent cultures) B. 
Representative blots and quantification of western blots show that levels of pGluA1 (S845) 
are increased with PregS in hippocampal and cortical neurons (10-12 independent 
cultures). Data represent mean ± SEM. *p < 0.05 vs VEH, **p < 0.01 vs VEH.  
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Fig. 10. 50 pM PregS-induced increase in S831 and S845 phosphorylation is 
concentration dependent and structure specific. 50 pM PEHS, 50 pM PREG and 50 fM 
PregS did not increase S831 (A) and S845 (B) levels in cortical neurons (3-5 independent 
cultures). Data represent mean ± SEM. *p < 0.05 vs VEH, **p < 0.01 vs VEH, not 
significant (n.s.) p >0.05. 
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Fig. 11. PregS-induced increase in GluA1 phosphorylation at S831 is dependent on 
CAMKII activation.  Cultures were preincubated with 10 µM KN62, 0.25 µM KN93, and 
0.25 µM KN92 for 30 min before VEH or 50 pM PregS treatment. KN62 and KN93 
(CAMKII inhibitors) block the PregS-induced increase in phosphorylation in cortical 
neurons (A), while KN62 blocks the effect in hippocampal neurons (B) (3-5 independent 
cultures). The inactive analog of KN93 (KN92) does not affect the increase in S831. Data 
represent mean ± SEM. **p < 0.01 vs VEH, # p < 0.05 vs PregS.  
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Fig. 12. PregS-induced increase in GluA1 phosphorylation at S831 is not dependent 
on PKC activation.  Cells were pretreated with 1 µM Go6983 for 30 min before VEH or 
50 pM PregS treatment. The effect of PregS is not blocked by the PKC inhibitor Go6983 
in both (A) cortical and (B) hippocampal neurons (3-5 independent cultures). Data 
represent mean ± SEM. **p < 0.01 vs VEH.  
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Fig. 13. 50 pM PregS increases phosphorylation of GluA1 at S845 via activation of 
PKA. The increase due to PregS is blocked by PKI-1422 amide (PKA inhibitory peptide)    
in cortical (A) but not in (B) hippocampal neurons (3-4 independent cultures). Data 
represent mean ± SEM. **p < 0.01 vs VEH, # p < 0.05 vs PregS.   
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(LTD-like) of glutamate receptors at the synapse (Nayak et al., 1996; Rao et al., 1997; Lu 
et al., 2001; Antonova et al., 2001). AMPA receptors are the major type of glutamate 
receptors that determine synaptic strength and are rapidly inserted into or removed from 
synapses.  The C-terminus of GluA1 encodes signals for AMPA receptor insertion upon 
synaptic activity and thus differs from the C-terminus of GluA2 which encodes signals for 
endocytosis and recycling of AMPA receptors (Lee et al., 2004). We therefore focused on 
the GluA1 subunit of AMPA receptors since they can be rapidly inserted in the synapse to 
bring about (LTP-like) changes in activity-dependent postsynaptic plasticity (Malenka and 
Bear, 2004; Huganir and Nicoll, 2013).  
 We asked whether a pM PregS-induced increase in intracellular Ca2+ could have an 
effect on surface expression and postsynaptic clustering of GluA1, by using PSD95 as a 
postsynaptic marker and VGlut1 as a presynaptic marker of putative excitatory synapses. 
The major finding of this study is the identification of a plausible molecular mechanism (s) 
underlying the effect of physiological concentrations of PregS in regulating synaptic 
plasticity. Our results suggest that PregS at physiological relevant concentrations induces 
AMPAR redistribution to postsynaptic specializations and increases presynaptic glutamate 
release. Increase in intracellular Ca2+ in the postsynaptic neuron induced by influx of Ca2+ 
can lead to the stimulation of Ca2+ -dependent kinases such as CAMKII, PKA and PKC 
(Lledo et al., 1995; Ling et al., 2002; Otmakhova et al., 2000).  A 10 min treatment of 
neurons with pM PregS induces an increase in S845 phosphorylation suggesting an 
involvement of PKA. Phosphorylation of S845 in the carboxy terminus of GluA1 by PKA 
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is necessary for insertion of GluA1-containing AMPA receptors in extrasynaptic sites (Oh 
et al., 2006).  
Protein-protein interactions of GluA1 C-terminus with intracellular proteins is 
required for trafficking. PSD95 is the prototypical member of the membrane-associated 
guanylate kinase (MAGUK) family and plays a critical role in synapse maturation and 
plasticity. It has been shown to regulate the incorporation of GluA1 into the synapse in an 
activity-dependent manner (El-Husseini et al., 2000; Ehrlich and Malinow, 2004).  Synapse 
Associated Protein (SAP97), another member of the MAGUK family of proteins associates 
via its PDZ domain with GluA1 and is also involved in GluA1 trafficking to the synapse 
(Nakagawa et al., 2004). The MAGUK proteins exhibit functional redundancy and the 
specific role of SAP97 versus PSD95 in promoting GluA1 trafficking remains unknown 
(Elias and Nicoll, 2007).   
Glutamate receptors and PKA are recruited into a macromolecular signaling 
complex by the interaction of SAP97 and the A-kinase activated anchoring protein (AKAP 
79/150). This facilitates the phosphorylation of GluA1 at S845 by PKA (Colledge et al., 
2000).  Interestingly, it has been recently shown that a 1 hr treatment with allopregnanolone 
activates PKA in primary neuronal cultures and increases spine density (Shimizu et al., 
2015). Using immunofluorescence, we observed an increase in surface GluA1 puncta as 
well as increased colocalization with PSD95, indicating an increase in synaptic surface 
GluA1 in dendrites, since PSD95 clusters and anchors AMPARs at the synapse. We also 
show an increase in GluA1 phosphorylation at S831. Activity-dependent phosphorylation 
of both S831 and S845 has been shown to recruit AMPARs to the surface membrane 
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(Henley and Wilkinson, 2013) (Fig. 13). We further demonstrate that PregS-induced 
increase in surface expression of GluA1 and its colocalization with PSD95 was blocked by 
MK-801/BIC, Ro 25-6981 and nifedipine. Blockade of GluA1-PSD95 co-localization with 
Ro 25-6981 suggests that pM PregS induced synaptic recruitment of GluA1 is dependent 
on GluN2B-containing NMDA receptors. Blockade of colocalization by nifedipine 
emphasizes the Ca2+dependency of this process. 
Whole cell recordings of hippocampal neurons show that 50 pM PregS elicits an 
increase in frequency of sEPSCs. This may be due to PregS positively modulating 
presynaptic glutamate release and/or PregS activating silent synapses and converting them 
to synapses containing NMDARs and AMPARs.  The dependence of the effect on L-type 
VGCC and NMDAR activation indicates that PregS acts, at least in part, via an increase in 
intracellular Ca2+. The increased phosphorylation of GluA1 at S831 suggests that PregS 
treatment would result in increased amplitude of sEPSCs; however, this was not observed. 
In addition, previous studies show that glycine-induced chemical LTP (chem-LTP) in 
primary cultured neurons increases sEPSC amplitude (Lu et al., 2001). This discrepancy 
may be due to the duration of recording time following stimulation with PregS. In general, 
induction of chem-LTP requires a post-incubation period of cells to be 1 hr in Mg2+-
containing ECS following stimulation with 3 min of 200 µM glycine in Mg2+-free ECS. 
We recorded 10-15 min after incubating cells with 50 pM PregS. It is possible that a longer 
treatment with PregS or a longer incubation period after PregS treatment is required to 
observe an increased amplitude, since Ca2+-regulated protein synthesis contributes to the 
maintenance of synaptic potentiation.  
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Unsilencing of AMPAR-silent synapses is induced via correlated pre-and 
postsynaptic activity, NMDAR activation and an increase in intracellular Ca2+ (Hanse et 
al., 2013). Our results suggest that PregS promotes activity-dependent insertion of 
AMPARs at the dendritic surface membrane, and subsequently induces the lateral diffusion 
of AMPARs to synaptic sites, which may result in increased synaptic strength and 
unsilencing of synapses. This PregS-induced increase in functional synapses could in turn 
plausibly lead to increased excitability of neurons ultimately manifesting as an increase in 
their own glutamate release.  
Finally, we investigated whether PregS at physiological relevant concentrations 
modulates spine density by using MAP2 immunostaining and farnseylated eGFP 
transfection to visualize dendrites and spines. Both approaches revealed that a 10 min 
treatment with 50 pM PregS does not affect the number of spines in dendrites, indicating 
that short-term exposure to PregS does not change the morphology or number of dendritic 
spines. However, it is still possible that continued exposure to PregS can change dendritic 
spine number and/or morphology, similar to estradiol.  
Low PregS levels in the hippocampus have been correlated to memory deficits, and 
the dysfunction of neurosteroid synthesis has been associated with the pathophysiology of 
cognitive disorders (Zorumski et al, 2000; Weill-Engerer et al., 2002; Belelli and Lambert, 
2005, Marx et al., 2009; Kreinin et al., 2014). Our work has demonstrated that 
physiological concentrations of PregS in the brain causes presynaptic changes in glutamate 
release and postsynaptic redistribution of receptors. These results suggest a likely 
molecular mechanism(s) for PregS involvement in learning and memory (reviewed by  
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Fig. 14. Schematic illustrating mechanism that may underlie pM PregS-induced 
increase in synaptic GluA1 surface expression. Summary diagram to illustrate the 
hypothesis that PregS at physiological relevant concentrations promotes trafficking of 
GluA1-containing AMPARs to postsynaptic sites, which is dependent on activation of L-
type VGCC and synaptic NMDAR activation, an increase in intracellular Ca2+, and 
involves phosphorylation of GluA1 at S831 and S845 by CAMKII and PKA, respectively. 
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Schumacher et al., 2006 and Smith et al., 2014b). However, further elucidation of how 
endogenous PregS mediates neuroplasticity is still required.   
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Chapter 3 
Pregnenolone sulfate promotes an increase in surface GluN2A containing NMDA 
receptors in hippocampal neurons 
 
Abstract 
The surface expression of NMDA receptors is regulated by activity-dependent 
processes during synaptic development.  We have shown earlier that the neuroactive steroid 
PregS increases NMDA receptor surface expression in rat DIV7 cortical neurons. We 
tested whether PregS at concentrations that are physiologically relevant induces NMDA 
receptor redistribution, increased surface expression and synaptic localization in rat 
hippocampal neurons. Brief treatment with pM concentration of PregS increased surface 
expression or clustering of extrasynaptic GluN2A in DIV15 rat hippocampal neurons, 
while not affecting GluN1 and GluN2B. Studies have shown that GluN1/GluN2B receptor 
complexes are inserted at synapses early in development and replaced by GluN1/GluN2A 
receptors upon neuronal activity. We demonstrate that this PregS-induced increase in 
surface GluN2A-containing receptors is dependent on serine/threonine kinase casein 
kinase 2 (CK2), a kinase previously been shown to regulate the NMDAR subunit switch. 
Furthermore, we show that PregS increases phosphorylation of S1480, a CK2 substrate, 
that is dependent on activation of L-type VGCC and GluN2B containing NMDARs. 
Therefore, we hypothesize that acute exposure to pM PregS primes the synapse for the 
GluN2 subunit switch by increasing the extrasynaptic insertion or clustering of GluN2A-
containing surface NMDA receptors. These novel findings contribute to an increased 
understanding of the physiological role of PregS in receptor trafficking, synapse maturation 
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and plasticity during development and emphasize the possible therapeutic value of PregS 
for synaptic dysfunction associated with neuropsychiatric and neurodegenerative 
disorders. 
 
Introduction 
NMDARs are expressed at excitatory synapses throughout the brain and have been 
shown to be instrumental in the regulation of synaptic plasticity. The NMDAR belongs to 
the ionotropic glutamate receptor family and is characterized by its high permeability to 
Ca2+ and voltage-dependent block by Mg2+. NMDAR activation leads to the influx of Ca2+ 
ions into the postsynaptic cell triggering -depending on the amount and duration of 
NMDAR activation- a cascade of specific Ca2+-sensitive intracellular events and the 
induction of bidirectional synaptic plasticity, such as long-term potentiation or long-term 
depression (Collingridge et al., 2004; Bliss and Schoepfer, 2004). The heteromultimeric 
NMDAR complex is composed of two glycine-binding GluN1 and two glutamate-binding 
GluN2 subunits. The GluN1 subunit is the obligatory subunit to form a functional receptor, 
while the GluN2 can be one or more of the four subtypes (GluN2A, GluN2B, GluN2C, and 
GluN2D) (Sheng et al., 1994). NMDAR subunit combinations are not static. They can vary 
depending on the brain region, while being tightly regulated during development, where 
glutamatergic neurotransmission is largely mediated by NMDARs. Synaptic NMDARs are 
replaced by NMDARs that laterally diffuse from extrasynaptic sites (Tovar and Westbrook, 
2002). NMDA receptor clusters can be located at extrasynaptic sites (on side of spines and 
on dendritic shafts) and can be either in transit to and from synapses or serve to make 
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contact with an adjacent processes, such as glia, axons, and dendrites (Petralia, 2012).  The 
surface and synaptic expression of the GluN2B - containing receptors predominates during 
the first postnatal week and is replaced by GluN2A - containing NMDARs in response to 
synaptic activity (Cull-Candy et al., 2001; Stocca and Vicini, 1998; Tovar and Westbrook, 
1999). The GluN2 subunit switch is believed to underlie developmental plasticity and to 
be critical to the functional changes of the NMDAR during development, since 
GluN1/GluN2B receptors have slower decay kinetics than GluN1/GluN2A receptors 
(Traynelis et al., 2010). Though widely studied, the molecular mechanism controlling the 
subunit switch and its implication to disease if disregulated remains elusive. Studies have 
shown that, similar to AMPA receptors, NMDAR surface expression is controlled by 
synaptic activity. Grosshans et al. (2002) demonstrated that during LTP surface NMDAR 
expression in the CA1 region increases, while Peng et al. (2010) observed a slow increase 
of NMDAR mediated EPSCs after using a LTP induction protocol at the CA1 synapse, 
which was accompanied by an intracellular Ca2+ dependent switch in GluN2 subunit 
composition. Swanger et al. (2013) demonstrated that activity-dependent dendritic 
synthesis via the 3′ untranslated region cytoplasmic polyadenylation element (CPE) of 
GluN2A mRNA is involved in synaptic insertion of GluN2A in hippocampal neurons. 
Recent studies have shown that the serine/threonine kinase casein kinase 2 (CK2) regulates 
the switch from GluN2B to GluN2A in an activity-dependent manner. CK2 phosphorylates 
GluN2B at serine 1480, which disrupts its association with scaffolding proteins such as 
PSD95. This results in the endocytosis of the subunit and drives increased surface 
expression of GluN2A (Sanz-Clemente et al., 2010).  In a follow-up study, the same group 
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showed that activated CAMKII allows CK2 and GluN2B interaction by forming a 
trimolecular complex increasing the phosphorylation of GluN2B by CK2 (Sanz-Clemente 
et al., 2013).  
The neuroactive steroid PregS has been shown to positively modulate glutamatergic 
neurotransmission and aid in the formation of synaptic connections during the early stages 
of development (Charalampopoulos et al., 2008, Kretz et al, 2004). A plethora of 
preclinical and clinical studies have implicated PregS as a cognitive enhancer and a 
potential therapeutic (reviewed by Smith et al., 2014b). Our laboratory previously has 
demonstrated that PregS potentiates NMDAR-induced currents in Xenopus laevis oocytes 
expressing GluN1A/GluN2A receptors in a manner consistent with the insertion of 
NMDARs in the surface membrane. This delayed-onset potentiation by PregS occurs via a 
noncanonical, pertussis toxin-sensitive, G protein-coupled, and Ca2+-dependent 
mechanism (Kostakis and Smith et al., 2013). More recently, we showed that PregS at 
physiologically relevant concentrations stimulates intracellular Ca2+ release and increases 
CREB phosphorylation in cultured rat cortical cells (Smith et al., 2014a). Here, we asked 
whether pM concentration of PregS modulates the redistribution of NMDA receptors on 
the surface membrane in rat primary neurons. We found that 10 min, 50 pM PregS did not 
change GluN1 and GluN2B clusters, however, we observed an increase in surface GluN2A 
puncta density and size, suggesting that PregS promotes redistribution of surface GluN2A. 
Furthermore, we showed that PregS phosphorylates the S1480 residue of the GluN2B 
subunit via a CK2 dependent mechanism, in addition to depending on L-type VGCCs and 
GluN2B containing NMDAR activation. Our novel finding provides evidence of PregS 
71 
 
inducing signaling processes that are crucial for developmental plasticity, thereby further 
emphasizing its hypothesized role as an endogenous modulator of synaptic function. 
 
 
Materials and Method 
 
Cell culture: Cortical and hippocampal cultures were prepared from E18 Sprague 
Dawley rats (Charles River, MA). Cortical cultures were prepared as described in Smith 
et al. (2014a). Dissected hippocampi were dissociated with 2.5 % trypsin and 0.1 % 
DNAse. Cells were suspended in neurobasal media containing 10 % horse serum, 1 % 
glutamine and 1 % pen/strep and plated on poly-l-lysine (1 mg/ml) coated glass coverslips 
at a cell density of 90,000 cells per well. One hour post-plating, the media was completely 
changed to neurobasal media containing 1 % B27, 1 % glutamine, and 1 % pen/strep. 
Cultures were maintained until use with partial media changes every 3-4 days.  
Immunocytochemistry: Cultured hippocampal neurons were treated for 10 min with 
VEH (0.05 % DMSO) and 50 pM PregS in HEPES solution (137 mM NaCl, 2 mM KCl, 3 
mM CaCl2, 4 mM HEPES, pH = 7.3). After treatment, cells were washed once with 1X 
PBS. Cells were fixed with 4 % PFA/ 4 % sucrose in 1X PBS for 10 min at 4 °C and 
blocked with 8 % BSA and 2 % donkey serum for 1 hr at room temperature (RT). Then 
cells were incubated with rabbit polyclonal anti-N-GluN1 antibody (1:500; Abcam) for 2 
hrs, followed by a 1 hr incubation with Alexafluor 488 donkey anti-rabbit (1:1000; 
Invitrogen). Coverslips were mounted onto glass slides using Gold Anti-fade with DAPI 
mounting reagent (Invitrogen). For rabbit polyclonal anti-N-GluN2A antibody (1:500; 
Abcam) and rabbit polyclonal anti-N-GluN2B (1:50; Abcam) the same protocol was 
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followed. Enhanced GFP (eGFP): Cultured hippocampal neurons were treated for 10 min 
with VEH or 50 pM PregS in HEPES solution. After treatment, cells were washed once 
with 1X PBS before they were fixed. Cells were fixed with 4 % PFA in 1X PBS for 1 hr at 
RT, permeabilized in 0.25 % Triton X-100 for 15 min, blocked with 5 % normal goat serum 
for 1 hr at RT and incubated with rabbit polyclonal anti-GFP antibody (1:500; Chemicon) 
for 2 hrs at RT, followed by 1 hr incubation with Alexafluor 488 goat anti-chicken (1:5000; 
Invitrogen). After postfixing for 15 min with 4 % PFA, permeabilized with 0.25 % Triton 
X-100 for 15 min, and blocked with 10 % donkey serum for 1 hr at RT, cells were incubated 
O/N at 4 °C with mouse monoclonal anti-PSD95 antibody (1:200; Abcam), followed by a 
1 hr incubation with Alexafluor 647 donkey anti-mouse (1:500; Invitrogen). 
eGFP transfection: pEGFP-GluN2A (Addgene plasmid # 17924) and pEGFP-
GluN2B (Addgene plasmid # 17925) were a gift from Stefano Vicini (Luo et al., 2002). 
pCI-EGFP-GluN1 wt was a gift from Andres Barria & Robert Malinow (Addgene plasmid 
# 45446, Barria and Malinow, 2002). Hippocampal cultures were prepared as described 
above. DIV7 cells were transfected using a modified calcium phosphate transfection 
method described in Xia et al. (1996). DMEM was prewarmed at 37 °C for 20 min. 
Conditioned media was removed from all the wells and kept in the incubator. Cells were 
washed once with warm DMEM and 500 µL of DMEM was added to each well and the 
plate was returned to the incubator for 15 min.  Per well (90,000 cells) 2 µg of DNA was 
used. In an Eppendorf tube, DNA, 10X CaCl2 and ddH20 were combined. Then an equal 
volume of 2X HEPES solution was added while gently vortexing the tube. The precipitate 
was allowed to form for 25 min at RT in the dark before adding it dropwise to each well. 
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The plate was returned to the incubator and the layer of precipitate was allowed to form 
for 40 min. Cells were then washed twice with warm DMEM and the conditioned media 
was added to the wells at the end. Cultures were maintained with partial media changes 
until use. 
Imaging: Fluorescent images were obtained by a Nikon deconvolution wide-field 
epiflourescence microscope using a 60X oil objective at FITC and/or 647 channels. The 
same exposure time was used for all the coverslips stained with the same antibody. For 
each coverslip, 7-12 fields were imaged.  
Image Analysis: Puncta were isolated by thresholding using the average 
background intensity multiplied by 1.5 for N-GluN1, 1.4 for N-GluN2A and 1.3 for GluN1-
GFP, GluN2A-GFP, and GluN2B-GFP (Lu et al., 2001) and quantified using Image J 
software (NIH) and a custom-made algorithm. Puncta size was limited between 3.3 to 100 
pixels (Ippolito and Eroglu, 2010). Puncta larger than 100 pixels, likely to be aggregates 
of smaller puncta were resolved into smaller puncta after thresholding using their 
background intensity. ROIs were selectecd by two independent investigators (3-5 ROIs per 
image from 7-10 images per treatment group from one independent culture). Colocalization 
analysis was performed via a manual count of the yellow puncta (red and green colocalized 
puncta) per dendritic length by two independent investigators. For GluN1, GluN2A and 
GluN2B with PSD95, only green and red puncta that overlapped by >75 % were included 
in the analysis. 
Western Blot: Hippocampal or cortical cultures were treated with 50 pM PregS or 
VEH at 37 0 C for 10 min. Cells were washed once, scraped and collected in ice cold PBS 
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solution supplemented with cOmplete protease inhibitor cocktail and PhosSTOP 
phosphatase inhibitor cocktail (Roche) and 1mM PMSF. Whole cell extracts were prepared 
in RIPA lysis buffer (in mM) Tris-HCl 500, pH 7.4, NaCl 1500, 2.5 % deoxycholic acid, 
10 % NP-40, EDTA 10, PMSF 1, Na3VO4 1, NaF 1, supplemented with cOmplete protease 
and PhosSTOP phosphatase inhibitor cocktails, and processed for Western blot. 
Membranes were blocked with 5 % milk for 1 hr. The membranes were then incubated 
with primary antibodies (1:1000; anti-pGluN2B (Pierce lab) or anti-GluN2B, (Alomone 
labs or Abcam) overnight at 4 °C. After the primary incubation the membranes were 
washed and incubated with a goat anti-rabbit IgG antibody (Santa Cruz Biotechnology) at 
a dilution of 1:2000 in 5 % nonfat dry milk for 1 hr at RT. pGluN2B and GluN2B were 
normalized to the total protein content through a ß-actin Western blot, and then the ratio of 
phosphorylated protein to total protein was calculated.  
Stock Solutions: PregS, PREG (Steraloids), nifedipine, TBB (R&D systems), were 
prepared in DMSO. Ro 25-6981 and BD1063 (R&D systems) were dissolved in water.  
Statistical Analysis: Statistical significance of obtained values was determined 
using Mann Whitney U t-test or column statistics t-test via Graphpad Prism. Significance 
is indicated where for VEH vs PregS, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 
0.0001.   
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Results 
 
50 pM PregS treatment promotes GluN2A surface expression 
We investigated whether NMDAR redistribution occurs in response to 10 min, 50 
pM PregS treatment by studying surface GluN1 subunit expression using a GluN1antibody 
that recognizes the extracellular N-terminus of the subunit in dissociated DIV15 and 
DIV21 hippocampal cultures under nonpermeant conditions (Fig. 15). The number and size 
of puncta (fluorescent protein aggregates) were measured to determine changes in surface 
receptor distribution of GluN1. We found that PregS did not change the density and size 
of surface GluN1 puncta in DIV15 and DIV21 hippocampal neurons (p = 0.921 and p = 
0.224 for DIV15 and p = 0.363 and p = 0.883 for DIV21, respectively, 3-6 independent 
cultures).  
Next, we asked whether PregS promotes a change in surface GluN2 expression and 
immunostained DIV15 and DIV21 hippocampal neurons with anti-GluN2A or anti-
GluN2B antibodies against the N-terminus.  A 10 min treatment with 50 pM PregS 
increases the density of surface GluN2A puncta in proximal dendrites of DIV15 
hippocampal neurons by 52 % from 8.6 to 13.1 puncta per 20 µM dendritic length (p < 
0.001) and puncta size by 29% (p < 0.001, 8 independent cultures, Fig 16). No change in 
surface GluN2A was observed with PregS treatment in DIV21 hippocampal neurons (3 
independent cultures). Immunostaining using the anti-GluN2B antibody did not yield 
reliable results due to nonspecific staining (not shown). The results suggest that PregS  
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Fig. 15. 10 min, 50 pM PregS treatment does not change GluN1 surface expression or 
redistribution in DIV15 and DIV21 hippocampal cultures. Representative images (A) 
and quantification (B) showing that N-GluN1 puncta density and size do not change in 
proximal dendrites after a 10 min exposure to 50 pM PregS in DIV15 hippocampal cultures 
(n = 6). C and D. 50 pM PregS does not have an effect on surface N-GluN1 puncta or size 
in DIV21 hippocampal cultures (n = 3). Graph represents means ± SEM, n = independent 
cultures. Scale bar, 20 µm and 5 µm for dendritic segment. ****p < 0.0001 vs VEH.  
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Fig. 16. 10 min, 50 pM PregS treatment promotes GluN2A surface expression or 
clustering in DIV15 hippocampal cultures. A. Representative images showing that N-
GluN2A surface expression or clustering is increased in proximal dendrites after a 10 min 
exposure to 50 pM PregS in DIV15 hippocampal cells. B. Quantification of puncta density 
and size of N-GluN2A (n = 8). C and D. 50 pM PregS does not have an effect on surface 
N-GluN2A puncta or size in DIV21 hippocampal cultures (n=3). Graph represents mean ± 
SEM, n = independent cultures.  Scale bar, 20 µm and 5 µm for dendritic segment.  
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exposure promotes aggregates or increases surface expression of GluN2A. A lack of 
change in surface GluN1 levels and an increase in surface GluN2A upon PregS exposure 
may also suggest that PregS could promote a switch from GluN2B to GluN2A containing 
NMDA receptors on the synaptic membrane. 
 
PregS-induced increase of surface GluN2A is dependent on CK2 activity  
CK2 has been shown to regulate the GluN2B subunit switch (Sanz-Clemente et al., 
2010). Therefore, we tested whether inhibition of CK2 by 4,5,6,7-Tetrabromo-2-
azabenzimidazole (TBB) would inhibit the PregS-induced increase in puncta density of 
GluN2A. We preincubated DIV15 hippocampal for 30 min in 25 µM TBB before applying 
50 pM PregS or VEH in the presence of TBB (Fig. 17). TBB blocked the PregS mediated 
increase in GluN2A implicating CK2 in the mechanism of action of PregS. Pappa et al. 
(2014) demonstrated that activation of sigma receptors (σ receptors) increased GluN2 and 
PSD95 synthesis, as well as surface expression of NMDARs. To determine whether PregS 
induced GluN2A surface expression is dependent on the activation of the σ1 receptor, an 
endoplasmic reticulum resident chaperone protein, we preincubated hippocampal cells 
with 1 µM BD1063, σ1 receptor antagonist, for 30 min before PregS application.. We 
found that inhibiting σ1 receptors did not modulate the effect of PregS on puncta density 
of GluN2A.  
 To test the hypothesis of a possible subunit switch and determine changes in 
synaptic localization of NMDARs due to PregS, we transfected hippocampal neurons with 
N-terminal GFP tagged GluN1, GluN2A and GluN2B and immunostained for GFP and 
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Fig. 17. 10 min, 50 pM PregS induced increase in number of N-GluN2A puncta is 
dependent on CK2 in DIV15 hippocampal cultures. A. 30 min preincubation with 25 
µM TBB blocked PregS-induced increase in puncta density of N-GluN2A, while 30 min 
pretreatment with BD1063 did not inhibit the increase (3 independent cultures). Graph 
represents mean ± SEM. *p < 0.05 vs VEH, ****p < 0.0001 vs VEH, not significant (n.s.) 
p >0.05. 
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PSD95 (postsynaptic marker). As observed when we probed for endogenous GluN2A, 
PregS increases the number of GluN2A puncta and size in GluN2A-overexpressed 
hippocampal cells (Fig. 18A). Puncta density was increased by 27% from 18.9 to 24.1 
puncta per 20 µm (p = 0.0028) and puncta size by 21 % (p < 0.0001, 3 independent cultures, 
Fig. 18B and C). TBB blocked the PregS-induced effect on puncta of GluN2A. PregS did 
not have an effect on colocalization of GluN2A with PSD95 (Fig. 18D). No change in 
puncta number or density was observed in GluN1 and GluN2B overexpressed cells after 
PregS treatment (Fig. 19). Colocalization of GluN1 and GluN2B with PSD95 was also not 
affected by PregS. Using coimmunoprecipitation, we confirmed that PregS does not change 
the number of GluN1, GluN2A and GluN2B subunits that associate with PSD95, by 
immunoprecipitating PSD95 from lysates and westernblotting for GluN1, GluN2A and 
GluN2B (Fig. 20). Together, these experiments indicate that PregS increases surface 
GluN2A expression or clustering at extrasynaptic sites without having an effect on GluN1 
and GluN2B.  
 
PregS increases phosphorylation of GluN2B at S1480 
Since we showed that PregS-induced increase of GluN2A was blocked by TBB, we 
asked whether PregS increases the phosphorylation of GluN2B at S1480, a known substrate 
of CK2. Previous studies have shown that CK2 expression is regulated during 
development, therefore, we tested if PregS modulates phosphorylation of S1480 at GluN2B 
in DIV10, DIV15 and DIV21 cortical cultures (Blanquet, 2000; Sanz-Clemente et al., 
2010). A phospho-specific antibody that recognized GluN2B when phosphorylated at  
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Fig. 18. 10 min, 50 pM PregS treatment promotes N-terminal GFP tagged GluN2A 
surface expression in DIV15 hippocampal cultures. A. Representative images showing 
that surface GFP-GluN2A expression is increased in proximal dendrites after a 10 min 
exposure to 50 pM PregS in DIV15 hippocampal cultures. Quantification of puncta density 
(B) and size (C) of GFP-GluN2A (3 independent cultures). D. Quantification of number of 
GluN2A-GFP puncta colocalized with PSD95. Graph represents means ± SEM. Scale bar, 
5 µm. **p < 0.01 vs VEH, ****p < 0.0001 vs VEH, not significant (n.s.) p >0.05. 
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Fig. 19. PregS does not affect N-terminal GFP tagged GluN1 and GluN2B in DIV15 
hippocampal cultures. A. Representative images showing that GluN1-GFP puncta 
number, size and colocalization with PSD95 is unchanged in proximal dendrites after a 10 
min exposure to 50 pM PregS in DIV15 hippocampal cultures. Quantification of puncta 
density (B) and size (C) of GluN1-GFP and colocalization of GluN1-GFP with PSD95 (D) 
(n = 3). E. Representative images showing that GluN2B-GFP is unchanged in proximal 
dendrites after PregS treatment in DIV15 hippocampal cultures. Quantification of puncta 
density (F) and size (G) of GluN2B-GFP and colocalization of GluN2B-GFP with PSD95 
(H) (n = 3). Graph represents means ± SEM, n =independent cultures. Scale bar, 5 µm. Not 
significant (n.s.) p >0.05. 
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Fig. 20. PregS does not change the amount of endogenous GluN1, GluN2A and 
GluN2B associated with PSD95. A. PSD95 was immunoprecipitated from lysates and 
probed for endogenous GluN1, GluN2A and GluN2B using specific antibodies. B. 
Quantification of amount of GluN1, GluN2A and GluN2B bound to PSD95 by 
normalization to the pull-down protein, PSD95. Graph represents means ± SEM. GluN1 
(n =2), GluN2A (n =5) and GluN2B (n =4), n = independent cultures. Work completed by 
R. Singh and R. Badolato.   
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S1480 was used for a Western blot (Fig. 21). We found that a 10 min, 50 pM PregS 
application increased pGluN2B levels in DIV15 cortical cultures by 37 % (p < 0.0001, 23  
independent cultures; Fig.21B) and in DIV21 cortical cultures by about 22 % (p = 0.021, 
6 independent cultures, Fig. 21C), while PregS did not have an effect in DIV10 cortical 
cells (p = 0.238, 3 independent cultures, Fig. 21A). Total GluN2B levels did not change 
with PregS treatment in DIV10 (p = 0.328), DIV15 (p = 0.535) and DIV21 cells (p = 0.188). 
Phosphorylation of GluN2B at S1480 disrupts the association of GluN2B with PSD95, 
which has been shown to result in a decrease in phosphorylation of Y1472 at GluN2B that 
is dependent on kinase cyclin-dependent kinase 5 (Cdk5) and Src family of kinases 
(Prybylowski et al., 2005; Zhang et al., 2008). We tested whether PregS decreases 
phosphorylation of Y1472 in DIV15 and DIV21 cortical neurons. However, we did not 
observe a change in pY1472 levels (3-5 independent cultures, not shown). Our results 
suggest that PregS promotes CK2 activity, thereby increasing phosphorylation of S1480 
on GluN2B.  
The increase in phosphorylation of S1480 due to CK2 is dependent on NMDAR 
activity and we have shown that pM PregS-induced increase in intracellular Ca2+ is 
GluN2B containing NMDAR and L-type VGCC activation dependent (Sanz-Clemente et 
al., 2010; Smith et al, 2014a). We, therefore, asked if 50 pM PregS-induced increase in 
pS1480 levels is contingent upon either L-type VGCC or GluN2B NMDAR activation.   
DIV15 cortical neurons were pretreated for 10 min with 10 µM nifedipine, an inhibitor of 
L-type VGCCs. 10 µM nifedipine suppressed the observed increase in GluN2B 
phosphorylation (Fig. 22). Co-application of 1 µM Ro 25-6981, a GluN2B specific  
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Fig. 21. 10 min, 50 pM PregS increases the immunoreactivity of pGluN2B (S1480) in 
DIV15 and DIV21 cortical neurons. DIV10 (A), DIV15 (B), and DIV21 (C) cortical 
neurons were treated with VEH or PregS for 10 min at 37 °C. Proteins were separated by 
SDS-PAGE followed by immunoblot with antibodies raised against pGluN2B (S1480) and 
GluN2B. Densitometric quantification shows that pGluN2B is significantly increased with 
PregS, compared to VEH, in DIV15 and DIV21 cortical neurons. PregS treatment of 
DIV10 cortical neurons did not show a change in phosphorylation of GluN2B (S1480). 
Graph represents means ± SEM. DIV10 (n=3), DIV15 (n=23), and DIV21 (n=6), (n) = 
independent cultures. **p < 0.01 vs VEH, ****p < 0.0001 vs VEH. Work completed by R. 
Singh and K. Sugunan.  
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Fig. 22. PregS induced phosphorylation of GluN2B at S1480 is dependent on CK2, 
GluN2B containing NMDAR, and L-type VGCC activation in DIV15 cortical 
neurons. Cortical neurons were preincubated with 25 µM TBB for 30 min and treated 
with VEH or 50 pM PregS for 10 min. Inhibition of CK2 suppressed the increase in 
S1480 levels (n = 3). Coapplication of 1 µM Ro 25-6981 blocked the PregS-induced 
increase in phosphorylation of GluN2B at S1480, while BD1063 (30 min preincubation) 
did not have an effect (n = 3). Preg, the unsulfated form of PregS, did not have an effect 
on phosphorylation of S1480 (n = 5). Graph represents means ± SEM. n = independent 
cultures. *p < 0.05 vs VEH, ***p < 0.001 vs VEH, not significant (n.s.) p >0.05. Work 
completed by R. Singh.  
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antagonist, with 50 pM PregS also inhibited the increase in pS1480 GluN2B levels. The 
increase in GluN2B phosphorylation was blocked by 25 µM TBB (30 min preincubation). 
As observed earlier, σ1 receptor inhibition by 1 µM BD1063 did not have an effect on 
pS1480 GluN2B levels (Pappa et al., 2014). We also show that the effect of PregS is 
structure-specific, since the unsulfated form, pregnenolone (Preg), did not increase pS1480 
(p = 0.617, 5 independent cultures). Together, our results show that pM PregS increases 
pS1480 GluN2B levels via activation of L-type VGCCs and NMDARs, particularly the 
GluN2B subtype.  
 
 
Discussion 
NMDARs are assembled into di-heteromeric and tri-heteromeric complexes in the 
ER and then packaged in the Golgi in vesicles that transport them to the surface membrane. 
GluN2 subunits are retained in the ER when GluN1 is not present and NMDAR subunits 
contain ER retention motifs preventing misfolded or unassembled complexes being 
trafficked to the cell membrane (Al-Hallaq et al., 2007; Horak et al., 2014). NMDA 
receptors are stabilized at the synapse by their interaction via PDZ domain with MAGUK 
membrane-associated guanylate kinase (MAGUK) proteins, such as PSD95 and synapse-
associated protein 102 (SAP102). The PDZ domain is located at the extreme C-termini of 
the GluN2 subunits. In addition to anchoring NMDARs, MAGUK proteins have been 
shown to serve as scaffolding proteins that facilitate the interaction of GluN2 with 
intracellular signaling molecules (Petralia et al., 2009). Activity at glutamatergic synapses 
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can stimulate the reorganization of NMDA receptors within the postsynaptic density (Kim 
and Sheng, 2004). Immunostaining of endogenous GluN1 and GluN2A and overexpressed 
GluN1, GluN2A and GluN2B receptor subunits show that pM levels of PregS induces an 
increase in surface GluN2A expression and/or clustering. PregS did not induce a detectable 
change in GluN1 subunit as determined with immunofluorescence. This finding suggests 
that there is no net change in the total number of surface NMDA receptors. It has been 
shown that GluN2A surface expression and synaptic localization increases after synaptic 
activity and the ratio of receptor subtypes is known to change during development with 
GluN2A containing NMDA receptors replacing GluN2B containing NMDA receptors 
(Wenzel et al., 1997; Barria and Malinow 2002; Traynelis et al., 2010). We have previously 
shown that PregS increases intracellular Ca2+ and CREB phosphorylation, both being a 
consequence of synaptic activity (Smith et al., 2014a). We hypothesized that PregS induces 
synaptic activation, which promotes a switch from GluN2B to GluN2A-containing 
receptors. However, we did not detect a decrease in GluN2B surface expression when we 
overexpressed GluN2B in hippocampal cells. We also did not see a change in synaptic 
localization of GluN2A when we studied colocalization and coimmunoprecipitation with 
PSD95, suggesting that observed changes due to PregS are limited to GluN2A-containing 
NMDARs located at extrasynaptic sites. NMDARs are inserted at extrasynaptic sites 
before moving laterally to the synapse (Petralia et al., 2009).  
Exceptions to the dichotomy that GluN2B is mainly extrasynaptic, while GluN2A 
is synaptic have been demonstrated by the presence of GluN2A on extrasynaptic sites. 
However, little is known about extrasynaptic GluN2A, including its regulation and 
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significance (Thomas et al., 2006; Petralia et al., 2012). We, therefore, propose that PregS 
may promote the initial stage of synapse maturation and plasticity by clustering or inserting 
extrasynaptic GluN2A. However, further experiments are required to study whether there 
is a change in endogenous surface GluN2B, since we have yet to find a good antibody 
specific for GluN2B. Another explanation is that PregS stimulates the clustering or 
insertion of GluN1/GluN2A/GluN2B tri-heteromeric receptor complexes, replacing di-
heteromeric GluN1/GluN2A and GluN1/GluN2B receptors (Tovar et al., 2013).  
Considering the change in expression of MAGUK proteins during development and 
association with GluN2 subunits, we have to consider other scaffolding proteins besides 
PSD95 to indicate synaptic localization. For example, a study has shown that GluN2A 
associates with PSD95, while GluN2B preferentially associates with SAP-102 during the 
early stages of development (Sans et al., 2000). Therefore, the effect of pM PregS on 
NMDARs at the synapse requires further investigation.  
To elucidate the mechanism underlying the increased surface expression of 
GluN2A, we asked whether PregS increased phosphorylation of GluN2B at S1480, a 
substrate of CK2. We found that PregS increased the pGluN2B levels, which was blocked 
by a CK2 inhibitor, indicating that PregS most likely acts at the synapse to stimulate CK2 
activity. We found that PregS had a more robust effect on S1480 in DIV15 than in DIV21 
cortical neurons, while not affecting DIV10 cells. This observation is consistent with CK2 
levels during development, which peaks during the second postnatal week, the critical 
period for the GluN2 subunit switch (Sanz-Clemente et al., 2010). We found that 
phosphorylation of S1480 due to pM PregS was dependent on GluN2B containing 
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NMDAR and L-type VGCC activation, which suggests that Ca2+ influx through both Ca2+ 
channels may result in increased activity of CK2. As previously shown (Sanz-Clemente et 
al., 2010), phosphorylation of GluN2B on S1480 was inhibited by NMDAR antagonists 
and tetrodotoxin.  
Our finding provides evidence that the endogenous neuroactive steroid might be 
involved in the developmental GluN2 subunit switch, thereby promoting synapse 
development and plasticity. However, it is not clear whether this might occur only through 
the CK2 mediated pathway, since PregS application results in a decrease in GluN2B on the 
surface and a decrease in phosphorylation of Y1472 on GluN2B is not observed. It is 
possible that increased surface expression and/or clustering of GluN2A is due to a separate 
mechanism that is independent of CK2 mediated GluN2B phosphorylation. Therefore, 
several known and possibly unknown mechanisms may act in a coordinated manner to 
replace GluN2B with GluN2A (Sanz-Clemente et al., 2013b). For example, Grau et al. 
(2014) has shown that dual specificity tyrosine-phosphorylation-regulated kinase 1A 
(DYRK1A) phosphorylates GluN2A at S1048 to prevent its internalization in primary 
neurons, resulting in increased surface expression of GluN2A. A 10 min stimulation with 
PregS might represent the beginning of a temporal sequence of events that eventually 
results in the GluN2 subunit switch. Nevertheless, our study suggests a novel function of 
PregS during the critical period of synapse development, warranting further investigation 
of PregS as a therapeutic for cognitive dysfunction. 
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Fig. 23. Schematic showing the Ca2+ and CK2 dependency for pM PregS-induced 
increase in surface GluN2A-containing NMDARs and phosphorylation of GluN2B at 
S1480. PregS increases synaptic activity and stimulates CK2 activity, resulting in the 
phosphorylation of S1480, which is dependent on GluN2B containing NMDAR and L-type 
VGCC activation. The increase in extrasynaptic GluN2A is also dependent on CK2 
activity, suggesting that exposure to PregS may induce an early phase of synapse 
maturation.  
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General Conclusions 
Chapter 1 
 
 Preclinical studies of PregS indicate that it is an endogenous neuromodulator of 
synaptic transmission.  
 Clinical studies support the therapeutic utlility of PregS for treating cognitive 
deficits observed in schizophrenia.  
 Further investigations are needed to understand the mechanism of action of 
endogenous PregS, since previous in-vitro and ex-vivo studies have shown effects 
of PregS at concentrations that are not consistent with levels measured in bulk 
brain tissue.  
 
Chapter 2 
 
 PregS at physiologically relevant concentrations increases presynaptic glutamate 
release and/or the activation of silent synapses.  
 PregS at physiologically relevant concentrations induces trafficking of AMPARs 
to the synaptic and extrasynaptic surface membrane, consistent with an increase in 
GluA1 phosphorylation at S831 and S845.  
 Our results suggest that PregS acts as a positive modulator of synaptic 
neurotransmission and induces molecular changes relevant to the induction of 
synaptic plasticity.  
 Our work sheds light on the underlyng mechanism by which PregS could 
potentially function as a cognitive enhancer.  
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Chapter 3 
 
 PregS, at a concentration that is consistent with levels found in the brain, 
increases levels of extrasynaptic GluN2A-containing NMDARs and 
phosphorylation of GluN2B S1480, a residue shown to be critical in the GluN2 
subunit switch during development.  
 Our results suggest that PregS induces activity-dependent changes in the receptor 
subunit composition of NMDARs at the synapse during the maturational period.  
 This discovery implies that PregS may play a novel role in the molecular 
mechanism underlying surface trafficking of NMDARs during synapse 
maturation.  
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Appendix I 
Section A: Summary of results from slice electrophysiology recordings studying the 
effect of PregS on synaptic neurotransmission 
 
Introduction  
Under basal conditions, stimulation of Schaeffer collateral afferents evokes field 
excitatory postsynaptic potentials (fEPSPs) in CA1 pyramidal neurons that are composed 
of AMPAR and NMDAR components. We hypothesized that PregS enhances local field 
potentials by positively modulating presynaptic and/or postsynaptic NMDARs. To test this 
hypothesis, current-stimulated fEPSPs in the CA1 of the hippocampus were studied upon 
application of PregS. The NMDAR and AMPAR components of the local field potentials 
were studied separately by isolating them using CNQX (in Mg2+-free aCSF) and DAP-5, 
respectively. The effect of PregS on presynaptic function were determined by using a 
paired pulse facilitation protocol. In addition, to understand the physiological relevance of 
CREB phosphorylation observed in cortical neurons, we examined whether the same 
phenomenon is seen in ex-vivo acutely prepared hippocampal slices. 
 
Methods 
Slice electrophysiology 
All experiments were carried out in accordance with the guidelines established by 
the Institutional Animal Care and Use Committee and the Laboratory Animal Science 
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Center of Boston University. Sprague Dawley rats aged P16-P30 were used for this study. 
They were housed at RT in a light-controlled room, with free access to food and water. The 
rats were anesthetized using isoflurane and decapitated. The brain was extracted during 
dissection, while the head was  submerged in ice-cold (4-5 °C) artificial cerebrospinal fluid 
(aCSF), which was  oxygenated with a gas mixture of 95% O2/5% CO2.The aCSF 
contained (in mM): 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 6 MgSO4, 1 CaCl2, and 
10 sucrose. The frontal lobe and cerebellum were sliced off and the brain was  mounted on 
a block. The brain was  hemisected and 400 μm-thick coronal slices containing the 
hippocampus was  cut on a Leica vibratome and transferred to an incubation chamber 
containing oxygenated aCSF maintained at room temperature. This aCSF contained  (in 
mM): 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 1.3 MgSO4, 2.6 CaCl2, and 10 
glucose. The brain slices were allowed to recover for 1 hr before recording. Slices were 
recorded at 28-29°C in a submerged thermostat-controlled recording chamber containing 
continuously oxygenated aCSF (flowing at a rate of 2 ml/min). Field recordings were 
obtained by glass microelectrodes containing aCSF (~1 megaohm), at a depth of ~100 μm. 
Potentials were recorded with an EPC-9 patch-clamp amplifier (HEKA Electronics, 
Germany), filtered, digitized, and stored on a computer. Data acquisition and analysis were 
done with an ITC-16 interface and PULSE-PULSEFIT software (version 8.11, HEKA 
Electronics). Constant current pulses of 0.1 ms duration were delivered at 0.05 Hz as test 
stimuli. FEPSPs were elicited by Schaffer collateral stimulation using a platinum 
concentric bipolor stimulating electrode and recorded with an electrode placed in the 
stratum radiatum of the CA1 region. The fEPSPs were monitored until a stable signal was  
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obtained. The control experiment recording consists of three parts: 1) a 20-min baseline 
recording b) LTP induction by tetanic stimulation consisting of three 100-Hz stimuli lasting 
for 1 sec at an intertrain interval of 20 sec, c) 30-min post-LTP baseline recording. The 
same control protocol was  used for LTD, except that the LTD induction protocol consists 
of 900 stimuli at 1 Hz. Only one LTP or LTD induction was  evoked for each slice to avoid 
metaplasticity.  
Western Blot  
The brain slices were allowed to recover for 1 hr before recording. Slices were 
recorded at 28-29°C in a submerged thermostat-controlled recording chamber containing 
continuously oxygenated aCSF (flowing at a rate of 2 ml/min). Following placement into 
the recording chamber, the slices were perfused with either a vehicle solution (0.05% 
DMSO in aCSF), a PregS solution (50 pM PregS dissolved in DMSO in aCSF), or a high 
K+ solution (aCSF with 50 mM KCl). The vehicle, PregS and 50 mM K+ solutions were 
perfused for 10 min, removed from the chamber, and hippocampal section were dissected 
and were immediately frozen at -80°C. The tissue was homogenized in an ice cold PBS 
solution (1 mM PMSF, protease/phosphatase inhibitors cocktail (Roche) in PBS) using a 
sonicator for one second. The samples were centrifuged at 4,000 rpm for 5 min at 4°C. The 
pellet was resuspended in 50 µL of RIPA buffer (1X RIPA, 1 mM PMSF, protease / 
phosphatase inhibitors cocktail (Roche), 1 mM Na3VO4, 1 mM NaF in water). The 
resuspended pellet was incubated at 4°C for 15 min, and centrifuged at 13,000 rpm for 10 
min at 4°C. Protein content of the supernatant was determined by Bradford assay. Aliquots 
of the supernatant were added to a solution of 1X loading dye and 0.1 M DTT in water so 
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that the final protein concentration was 30 µg/µL. Solutions were boiled at 95°C for five 
min. Proteins were separated by 10% SDS-PAGE, transferred to a nitrocellulose 
membrane, and then blocked with either 5% BSA (pCREB) or 5% milk (CREB) for one 
hour. The membranes were then incubated with primary antibodies (1:1000; anti-pCREB 
and anti-CREB from Santa Cruz Biotechnology) overnight at 4°C. After the primary 
incubation the membranes were washed and incubated with a goat anti-rabbit IgG antibody 
(Santa Cruz Biotechnology) at a dilution of 1:2000 in 5% nonfat dry milk for one hour at 
room temperature and visualized using ECL(+) and radiography film.      
Analysis 
The Western blot membranes results were analyzed by comparing VEH, PregS, and 
K+ band intensity on the film. pCREB and CREB were normalized to the total protein 
content through a ß-actin Western blot, and then the ratio of pCREB to CREB was 
calculated. Experimental groups that did not show an increase in pCREB relative to CREB 
following 50 mM K+ treatment were discarded. 
Stock Solutions 
PregS (Steraloids) was  prepared in dimethylsulfoxide (DMSO; 0.05%). CNQX 
and D-AP5 (R&D systems) were dissolved in water.  
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Results  
A. Pharmacologically and physiologically validate recorded current stimulus-induced 
fEPSPs in rat hippocampal slices.  
To confirm that fEPSPs were indeed comprised of glutamatergic synaptic events, 
several control experiments were performed (Fig. 24). Applying 10 µM CNQX, an AMPA 
receptor antagonist, resulted in a substantial reduction of fEPSPs. Switching from control 
aCSF solution to Mg2+-free aCSF, increased the fEPSP response size, indicating an 
increase in depolarization due to unblocking of NMDA receptors. The observed fEPSPs, 
therefore, account for NMDA and AMPA receptor activation. To show that 
neurotransmission mediated by stimulation of Schaeffer collaterals are under GABAergic 
control, 10μM bicuculline methiodide, a GABAA receptor antagonist, was applied resulting 
in an increase in the amplitude of the fEPSP, the appearance of longer-latency fEPSPs, and 
a shift in the baseline. LTP was induced in control slices (3 slices from 3 rat pups) with an 
estimated increase of 25% in fEPSP slope (Fig. 25). However, the success rate in obtaining 
LTP has been very low (20%) and further experiments using PregS could not be completed 
(insufficient sample size). Paired-pulse facilitation (PPF) at the Schaffer collateral-to-CA1 
synapse was studied by applying paired stimulation pulses at three interstimulus intervals 
(ISI): 10, 50 and 100 ms (Fig. 26). The paired pulse ratio is the relative facilitation 
calculated as PPF2/PPF1 (PPF1 denoting the slope of the first fEPSP and PPF2 denoting 
the slope of the second fEPSP). At an interstimulus interval (ISI) of 50 ms, 30nM PregS 
seems to decrease facilitation, compared to its control (8 slices from 4 rat pups). We 
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confirmed that the second peak had a larger slope than the slope of the first fEPSP. The 
ratios for the 10, 50, and 100 ms ISIs were also consistent with the literature. There was a 
trend towards an increase in the slope ratios following the 50 ms ISI, which is consistent 
with the residual calcium hypothesis reflecting the release probability of the presynaptic 
cell.  
B. Determine the effect of PregS on the NMDAR and AMPAR components of current 
stimulus-induced fEPSPs in rat hippocampal slices.  
To reproduce the results obtained by Sliwinski et al. (2004), the slice was perfused 
for 10 min with 300 nM PregS prior to LTP induction (3 slices from 2 rat pups).  Unlike 
seen by Sliwinski et al., we observed a small increase (about 8 %) in fEPSPs (Fig. 27). 
However, we were unable to study the potentiating effect of 300 nM PregS on LTP since 
LTP could not be induced in the slices. We did not determine whether 300 nM PregS 
positively modulated the AMPAR and/or the NMDAR component of fEPSPs. A 10 min 
perfusion with 30 nM PregS did not have an observable effect on fEPSPs (6 slices from 3 
rat pups). In addition, no effect of 30 nM PregS on the NMDA receptor component of 
fEPSPs was seen when isolating NMDA receptor mediated fEPSPs using 10 µM CNQX 
in Mg2+-free aCSF (2 slices from one rat pup; Fig. 28).    
C. Determine whether 50pM PregS increases phosphorylation of CREB in rat 
hippocampal slices.  
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To understand the physiological relevance of the PregS-induced CREB 
phosphorylation observed in cortical neurons, we examined whether the same phenomenon 
is seen in an ex-vivo acutely prepared hippocampal slice, which is a relatively functionally 
intact and well-characterized system. A 10 min 50 pM PregS treatment increases pCREB 
in hippocampal slices by 64.8%, compared to vehicle (Fig. 29). Slices in experimental 
groups that did not show an increase in pCREB relative to CREB following K+ treatment 
were discarded. 
Discussion 
Preliminary studies in our lab show that 30 nM PregS applied for 10 min do not 
change fEPSPs, while 300 nM PregS induces a small increase in fEPSPs. However, there 
is a possibility that PregS may have been degraded by sulfatases present in the slice. Or, 
since the PregS-induced Ca2+ release was observed in embryonic primary cultured neurons, 
the hippocampal slice system could be different (developmental stage, receptor expression, 
resting membrane potential, and/or amount of inhibitory input) to the extent that PregS at 
these low concentrations does not show a measurable and significant effect on 
neurotransmission. Therefore, despite the preliminary field recording results obtained in 
slices, future studies need to address whether PregS accentuates LTP and/or LTD, since 
we have observed LTP-like changes in DIV21 hippocampal cultures. The break-down of 
PregS may be circumvented in the slice by using a sulfatase inhibitor and/or increase the 
time of PregS perfusion, though a caveat is that a sulfatase inhibitor specifically blocking 
only the desulfation of PregS is not available. In a separate study, we showed that 50 pM 
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PregS increases CREB phosphorylation. We did not determine by which signaling pathway 
the increase in pCREB is induced. However, this important finding conveys that picomolar 
concentrations of PregS have a physiological relevant effect and this result support the 
hypothesis that PregS can induce cellular signaling events that underlie long-term memory 
formation.  
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   aCSF
    Mg2+-free aCSF   10 µM CNQX 10 µM BIC
 
Fig. 24: Representative traces showing the effect of modulators of synaptic 
transmission on fEPSPs. FEPSP slopes recorded from hippocampal slice (rat age = P15-
32) are shown before (baseline, aCSF), and after perfusion of Mg2+-free aCSF, application 
of 10 µM CNQX or 10 μM bicuculline methiodide (BIC). Baseline stimulation frequency 
was 0.05Hz and pulse duration was 0.1ms.   
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Fig. 25: fEPSP slope before and after induction of LTP in control slices. A. fEPSP 
slopes (mean±SEM) recorded from hippocampal slice (rat age = P14-P28) are shown 
before (baseline) and after LTP induction (n=3). LTP induction (indicated by arrow) = 3 x 
100Hz. B. Representative traces showing fEPSP before, 20 sec and 1 hr after LTP 
induction. 
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Fig. 26: PPF electrophysiological recordings testing VEH perfusion on PPF at 10, 50, 
and 100 ms ISIs. A. PPF electrophysiological recordings testing three ISIs are shown. A 
given ISI was tested every 20 seconds until twenty consecutive stable responses were 
collected. B. Quantification of PPF data (mean±SEM).  
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Fig. 27: Effect of 300 nM and 30 nM PregS on fEPSP slope. A. fEPSP slopes recorded 
from hippocampal slice are shown before (baseline), during, and after 30 nM PregS 
application (rat age = P15-32, 6 slices). B. fEPSPs before (baseline) and during 300 nM 
PregS application (rat age = P41-44, 3 slices). LTP was induced in all slices after the 10-
min 300 nM PregS perfusion but LTP did not occur (not shown). C. Quantification 
showing that 300 nM PregS increases slightly fEPSPs, while 30 nM PregS does not change 
fEPSPs. Baseline stimulation frequency was 0.05 Hz and pulse duration was 0.1 ms. All 
slope values were normalized to the mean baseline slope. Quantification is expressed as 
mean± SEM. *p < 0.05 vs VEH.  
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Fig. 28: Sample experiment studying the effect of 30 nM PregS on NMDAR 
component of fEPSP. A. fEPSP slopes recorded from hippocampal slice (rat age = P16) 
are shown. After establishing a baseline for 10 min, NMDA receptor currents were isolated 
by switching to Mg2+-free aCSF containing 10 μM CNQX. The effect of 30 nM PregS was 
studied before introducing 50 μM DAP-5 allowing us to confirm that the observed fEPSPs 
were due to activation of NMDARs. At the end, all the compounds were washed out, 
confirming that the slice was still healthy and evoking current-stimulated fEPSPs. B. 
Representative fEPSP traces recorded from hippocampal slice (rat age = P16) are shown.   
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Fig. 29: 50 pM PregS increases the pCREB content of a hippocampal slice.A. Sample 
western blot bands. The VEH, PregS, and K+ treatment groups are shown, with the pCREB 
and ß-actin content of the slices visualized. B. Quantification of band intensity of the VEH, 
50pM PregS, and the high K+ slices following the pCREB antibody incubation was 
compared. Data represent mean±SEM. 
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Section B: Summary of results from testing the effect of different 50 pM PregS 
treatment paradigms on spine density of DIV21 hippocampal neurons 
 
 
Introduction  
 
We tested the hypothesis that PregS at physiological relevant concentrations 
increases excitatory synaptic input resulting in a compensatory decrease in dendritic spines. 
(See Chapter 1 and 2 for background on dendritic spines).   
 
Method 
 
(See Chapter 2 for details on culturing method).  
 
Immunocytochemistry 
Cultured hippocampal neurons were treated for 10 min or 30 min with VEH and 50 
pM PregS in HEPES solution. Two additional treatment regimen were tested: 10 min of 50 
pM PregS followed by 60 min in conditioned media and 30 min of 50 pM PregS followed 
by 40 min in conditioned media. After treatment, cells were washed once with 1X PBS 
before they were fixed. Cells were fixed with 4% PFA in 1X PBS for 1 hour at RT, 
permeabilized in 0.25% Triton X-100 for 15 min, blocked with 4% normal goat serum for 
one hour at RT and incubated with mouse monoclonal anti-MAP2 antibody (1:2000; Sigma 
Aldrich) overnight at 4°C, followed by a one hour incubation with Alexafluor 488 goat 
anti-mouse (1:500; Invitrogen).  
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eGFP transfection  
Cells were transfected using the Amaxa Basic Neuron SCN Nucleofector kit and 
the Nucleofector device (LONZA) with farnesylated-eGFP cDNA, according to the Lonza 
protocol. Per 100,000 cells 0.5µg of DNA was used. After plating transfected cells on 
confocal dishes, 50,000 nontransfected cells were added to each dish. Cultures were 
maintained until use. Partial media was changed three days after plating and then once a 
week until use (DIV 21).  
 
Imaging  
Fluorescent images of MAP2 stained cells were obtained by a Nikon deconvolution 
wide-field epiflourescence microscope using a 100X oil objective. The same exposure time 
was used for all the coverslips stained with the same antibody. For each coverslip, 10-15 
fields were imaged. Confocal images of eGFP tranfected cells were acquired using a Zeiss 
LSM 710 laser scanning confocal microscope with a 100X oil immersion objective lens at 
a resolution of 0.042 x 0.042 x 0.38µm per voxel.  Fluorescence is excited using 488 nm 
light. Acquired spine images were deconvolved using AutoQuant (MediaCybernetics). 
Investigators were blinded during analysis of MAP2 stained images. Neuron tracing and 
spine count were performed using Neuronstudio software by two independent 
investigators. Spines of eGFP transfected cells were manually counted via Image J software 
(NIH) by two independent investigators. 
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Results 
MAP2 immunostaining of primary hippocampal neurons showed that 30 min 50 
pM PregS treatment followed by 40 min in conditioned media seems to decrease dendritic 
spine density in proximal dendrites by about 18% (p = 0.054, 3 independent cultures; Fig. 
30). The other three treatment groups (10 min, 30 min, and 10 min PregS followed by 60 
min in conditioned media) did not show an effect on spine density in both proximal and 
distal dendrites.  
We used an additional method for visualizing spines and transfected hippocampal 
neurons with farnesylated eGFP and tested the same treatment regimen (30 min PregS, 40 
min media, Fig. 31). The transfection itself did not affect the morphology of neurons and 
spine density was comparable to MAP2 stained cells (10-11 spines/20µm). Quantitative 
analysis of spine density of eGFP transfected cells revealed that 50 pM PregS decreased 
the number of spines present on proximal by about 15% and distal dendrites by about 34% 
(p = 0.0094 for proximal dendrite and p < 0.0001 for distal dendrites, 4 independent 
cultures). Any change in spine shape has not been determined yet.  
 
Discussion  
We investigated whether PregS at physiological relevant concentrations modulates 
spine density by using two methods to visualize spines - MAP2 immunostaining and 
farnseylated eGFP transfection. Both approaches revealed that a 30 min treatment of 50 
pM PregS followed by 40 min in conditioned media decreased the number of spines in 
proximal dendrites. Cells transfected with eGFP also showed that PregS decreases spine 
111 
 
density in distal dendrites as well. The reason for this discrepancy is not clear. However, 
spines were more clearly visible in eGFP transfected cells and were imaged at a higher 
resolution using a confocal microscope (versus a wide-field fluorescence microscope for 
MAP2 stained cells). Therefore, the spine count obtained from eGFP transfected cells 
should be more accurate.  
Taken together with the immunostaining and whole cell recording results (Chapter 
2), the spine data suggest that PregS induces an acute increase in synaptic transmission, 
which may result with time in a compensatory decrease in spines. Or, PregS may promote 
via an unknown mechanism pruning of synaptic contacts and therefore cause the retraction 
of spines. We cannot completely exclude the possibility that PregS is having a neurotoxic 
effect. However, visual inspection of PregS- treated neurons did not show any signs of cell 
death (dendritic blebbing), compared to VEH-treated cells.  
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Fig. 30. Effect of  50pM PregS on spine density in proximal and distal dendrites in 
MAP2-stained neurons A. Representative image of dendritic spines visualized using 
MAP2-immunostaining. Scale bar, 10 µm. B. Quantification of spine density in MAP2 
stained cells showing that 10 min, 30 min, and 10 min followed by 60 min in conditioned 
media of 50 pM PregS treatment does not change number of spines in proximal and distal 
dendrites. 30 min of PregS treatment followed by 40 min in conditioned media seems to 
decrease number of spines in proximal dendrites (3 independent cultures). Data represent 
mean±SEM. 
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Fig. 31: 30 min, 50 pM PregS treatment followed by 40 min in conditioned media 
decreases dendritic spine density in proximal and distal dendrites in DIV21 
hippocampal cultures. A. Representative image of dendritic spines in anti-GFP stained 
farnesylated eGFP transfected neuron. Scale bar, 10 µm. B. Quantification of spine density 
showing that 30 min followed by 40 min in conditioned media of 50 pM PregS treatment 
decreases number of spines in proximal and distal dendrites (4 independent cultures). **p 
< 0.01 vs VEH, ****p < 0.0001 vs VEH. Data represent mean±SEM.   
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Section C: Pregnanolone Hemisuccinate Inhibits NMDA Receptors with Selectivity 
for the GluN1A/GluN2A Subtype 
 
Introduction 
There is strong evidence that glutamate receptors play a major role in relapse of 
cocaine addiction. However, effective treatments for prevention of relapse are still lacking 
and there has been increasing interest in developing glutamate receptor based therapeutics 
for the treatment of cocaine addiction that do not interfere with normal glutamate receptor– 
dependent processes (Schmidt and Pierce, 2010). Our lab has shown that the neuroactive 
steroid pregnanolone sulfate is a negative allosteric modulator of ionotropic glutamate 
receptors (Yaghoubi et al., 1998; Malayev et al., 2002) and that pregnanolone 
hemisuccinate (3α5βHS or PAHS, Fig. 32), the synthetic analogue of pregnanolone sulfate, 
inhibits reinstatement of cocaine seeking behavior in rats (Ratner et al., 2007).    
 In order to determine the receptor and subtype selectivity of 3α5βHS, recombinant 
NMDA, AMPA and GABAA receptor subtypes were expressed in Xenopus laevis oocytes 
and two electrode voltage-clamp recordings were performed.  
 
Methods 
Xenopus laevis frog oocytes extraction  
A frog was placed in a 0.15% Tricane solution for 30 min. Follicular sacks of 
oocytes were removed following lateral abdominal incision and placed in Ca2+-free Barth’s 
solution (in mM: 84 NaCl, 2.4 NaHCO3, 0.82 MgSO4, 1KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 
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7.5 TrisHCl, 2.5 pyruvate and 100U/ml penicillin/streptomycin; pH 7.4). Oocytes were 
transferred into a 1.5 mg/ml solution of collagenase and incubated for 60-75 min, until 
defolliculated. The oocytes then were rinsed with Ca2+-free Barth’s solution 2-3 times and 
then left in Ca2+-free Barth’s solution in an incubator at 18-20°C. 
RNA injection  
Plasmids were linearized with appropriate restriction enzymes prior to in vitro 
transcription using mMESSAGE mMACHINE™ High Yield Capped RNA Transcription 
kits. Oocytes (at maturation stage V-VI) were selected from the batch and injected with 
with cRNAs (0.5 – 5 ng/cRNA) using an electronic microinjector. Injected oocytes were 
kept at 18°C in Barth's solution for one day. 
Two-voltage clamp electrophysiology  
Two-electrode voltage clamp recordings from oocytes expressing NMDA, AMPA, 
GABAA receptor subtypes were performed at room temperature (23 - 25°C) with a -70 mV 
holding potential for NMDA and GABAA receptors and -90 mV for AMPA receptors. 
Electrodes were filled with 2M KCl, which yielded a resistance of 1-3 M. Salt bridges were 
filled with 1 M KCl and connected to the salt and perfusion well. The transmembrane 
current was filtered at 10 Hz and digitized at 100 Hz. The oocyte recording chamber was 
continuously perfused with Ba-Ringer solution. The Ca2+ and Mg2+ free Ba-Ringer 
perfusion buffer contains in (mM): 96 NaCl, 2 KCl, 1.8 BaCl2 and 5 HEPES, 0.5% DMSO, 
pH 7.5. Drugs were applied for 30 s followed by 180 s wash by a gravity-driven external 
perfusion system at a rate of 40 μl/sec. Data acquisition and perfusion were controlled by 
custom-written software implemented in LabVIEW. All coapplications of agonist + 
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3α5βHS were normalized by the response to a standard concentration of agonist to 
eliminate differences in receptor expression and the run-down effect. Peak agonist-induced 
currents in the presence of 3α5βHS were determined relative to the adjacent response of 
agonist alone.  
Data analysis 
 Dose-response data was analyzed by non-linear regression using the logistic 
equation:  
Relative current = Emax/(1+(EC50/c)nH) 
c – concentration of drug  
nH – Hill coefficient  
EC50 – concentration producing 50% of maximal response  
Emax – maximum response  
The peak current values were normalized and shown as a fraction of control current 
response.  
 
Results  
Pregnanolone Hemisuccinate (3α5βHS or PAHS) inhibits the NMDA 
GluN1A/GluN2A and GluN1A/GluN2B receptor subtypes. The potency at the 
GluN1A/GluN2A subunit combination is 0.32 μM and the efficacy is -20.0 % (n=14, n= 
number of oocytes). 3α5βHS has a 13-fold lower potency at the GluN1A/GluN2B subtype 
(n=10) compared to GluN1A/GluN2A (EC50= 4.3 μM) but exhibits similar efficacy (-
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21%). The GluN1A/GluN2C (n=5) and GluN1A/GluN2D (n=5) subtype shows slight 
potentiation at concentrations greater than 10 μM (Fig. 33).  
 All four subtypes of the GABAA receptor (α1β2γ2s, α2β2γ2s, α3β2γ2s) show 
inhibition by 3α5βHS with their efficacy values around -20 %. The EC50 for α1β2γ2s is 6.2 
μM (n=7) and for α3β2γ2s is about 9.3 μM (n=12). In comparison, the potency for the 
α3β2γ2s (n=12) and α5β2γ2s (n=5) subtypes could not be determined.  
 The AMPA receptor subtype GluA1 is slightly inhibited by 3α5βHS, however, 
3α5βHS has no effect on GluA3 and the heteromeric GluA1/GluA2 receptor. The EC50 
could not be determined. The IV curves of GluA1/A2 and GluA1 were determined. 
According to Boulter et al., 1990, GluA1-injected oocytes display inward rectification and 
a reversal potential near -40 mV, whereas the GluA1 and GluA2 combination has an almost 
linear IV plot with a reversal potential at about -10 mV. Similar results were obtained here 
(not shown).  
 
Discussion 
We observed that 3α5βHS inhibits all four subtypes of the NMDA receptor with 
similar efficacies (about -20%). However, the potency at the GluN1A/2A subunit 
combination is 10 to 30 fold higher as compared with the GluN1A/GluN2B, GluN2C, and 
GluN2D subtypes. Four subtypes of the GABAA receptor (α1β2γ2s, α2β2γ2s, α3β2γ2s, and 
α5β2γ2s) are inhibited by 3α5βHS with potencies ranging from 6-9 μM and maximum 
efficacy of -18%, while AMPA receptor subtype GluA1 is slightly inhibited. We propose 
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that the use of a multifunction compound acting on multiple receptor subtypes such as 
3α5βHS may be effective in the treatment of cocaine seeking. 
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 Fig. 32: Chemical structure of pregnanolone hemisuccinate and pregnanolone sulfate. 
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Fig. 33: 3α5βHS inhibits all four subtypes of NMDA receptors tested. Dose-response 
curves indicate 3α5βHS negatively modulates different subtypes of NMDA receptors. It is 
most potent at the GluN1A/GluN2A subtype (EC50: 0.32 μM), followed by 
GluN1A/GluN2B, GluN1A/GluN2D and GluN1A/GluN2C. Data represent mean±SEM. 
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Fig. 34: Effect of 3α5βHS on subtypes of GABAA receptors. Four subtypes of the 
GABAA receptor (α1β2γ2s, α2β2γ2s, α3β2γ2s, and α5β2γ2s) are inhibited by 3α5βHS with 
potencies ranging from 6-9 μM and maximum efficacy of -18%. Data represent 
mean±SEM. 
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Fig. 35: Effect of 3α5βHS on subtypes of AMPA receptors. Dose-response curves 
indicate 3α5βHS inhibits the GluA1 AMPA receptor subtype slightly, but has no effect on 
the heteromeric GluA1/GluA2 and GluA3 receptors. Data represent mean±SEM. 
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Table 5: Summary table of receptor and subunit selectivity study for 3α5βHS. Potency 
and efficacy values obtained from the receptor and subunit selectivity study for 3α5βHS. n 
= number of oocytes. Data represents mean. 
 
 
NMDAR GluN1/GluN2A GluN1/GluN2B GluN1/GluN2C GluN1/GluN2D
EC50 (µM) 0.32 4.3 12.3 9.8
Efficacy (%) -20 -21 -22 -20
n 14 10 5 5
GABAAR α1β2γ2s α2β2γ2s α3β2γ2s α56β2γ2s
EC50 (µM) 6.2 NA 9.3 NA
Efficacy (%) -18 -17 -15 no effect
n 7 5 12 5
AMPAR GluA1 GluA1/GluA2 GluA3
EC50 (µM) NA NA NA
Efficacy (%) -13 No effect -8
n 8 3 6
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